Next Article in Journal
Understanding the Golgi Apparatus and Intracellular Transport Pathways
Previous Article in Journal
High-Loaded Copper-Containing Sol–Gel Catalysts for Furfural Hydroconversion
Previous Article in Special Issue
Antibiotic-Therapy-Induced Gut Dysbiosis Affecting Gut Microbiota—Brain Axis and Cognition: Restoration by Intake of Probiotics and Synbiotics
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 24
Issue 8
10.3390/ijms24087548
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Zonulin as a Potential Therapeutic Target in Microbiota-Gut-Brain Axis Disorders: Encouraging Results and Emerging Questions

by
Apor Veres-Székely
1,2,
Csenge Szász
1,
Domonkos Pap
1,2,
Beáta Szebeni
1,2,
Péter Bokrossy
1 and
Ádám Vannay
1,2,*
1
Pediatric Center, MTA Center of Excellence, Semmelweis University, 1083 Budapest, Hungary
2
ELKH-SE Pediatrics and Nephrology Research Group, 1052 Budapest, Hungary
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2023, 24(8), 7548; https://doi.org/10.3390/ijms24087548
Submission received: 17 March 2023 / Revised: 5 April 2023 / Accepted: 18 April 2023 / Published: 19 April 2023
(This article belongs to the Special Issue Molecular Aspects of Microbiota–Gut–Brain Axis Signaling)
Browse Figure
Review Reports Versions Notes

Abstract

:
The relationship between dysbiosis and central nervous diseases has been proved in the last 10 years. Microbial alterations cause increased intestinal permeability, and the penetration of bacterial fragment and toxins induces local and systemic inflammatory processes, affecting distant organs, including the brain. Therefore, the integrity of the intestinal epithelial barrier plays a central role in the microbiota–gut–brain axis. In this review, we discuss recent findings on zonulin, an important tight junction regulator of intestinal epithelial cells, which is assumed to play a key role in maintaining of the blood–brain barrier function. In addition to focusing on the effect of microbiome on intestinal zonulin release, we also summarize potential pharmaceutical approaches to modulate zonulin-associated pathways with larazotide acetate and other zonulin receptor agonists or antagonists. The present review also addresses the emerging issues, including the use of misleading nomenclature or the unsolved questions about the exact protein sequence of zonulin.

1. Introduction

Emerging literary data have revealed a dynamic bidirectional interaction between gut microbiota and the nervous system, described by the microbiota–gut–brain axis (MGBA) [1].
Various factors regulate microbial composition, including stress, nutritional habits, environmental impacts, and in parallel, luminal agents in gut affect neural functions [1,2]. The complex communication between microbiota and brain is continuous via inflammatory mediators, neurotransmitters, neuroactive microbial metabolites, and vagus and enteric nerves, among others [1]. The importance of MGBA was revealed by numerous human studies that demonstrated a correlation between altered composition of gut microbiota and neurological disorders, including Parkinson’s disease, Alzheimer’s disease, anxiety, depression, and autism both in children and adults [2,3,4]. Intestinal permeability is a key factor in this process determining the penetration of luminal elements into the circulation [5]. The barrier function of the intestinal epithelial layer is provided by intercellular junctions, including tight junction (TJ), adherens junction, and desmosome [6]. In the development of “leaky gut”, TJs and their component, the zonula occludens 1 (ZO-1), play a crucial role. ZO-1, also known as tight junction protein 1 (TJP-1), is a membrane-associated protein that ensures the basolateral cell–cell adherence of intestinal epithelial cells by cross-linking the TJ transmembrane proteins (claudin, occludin, junction adhesion molecule) and the actin cytoskeleton [7,8].
In 2000, the research group of Fasano reported the discovery of zonulin, a human protein analogue of the Vibrio cholerae-derived Zonula occludens toxin (Zot), regulating paracellular permeability through protein kinase C (PKC)-dependent rearrangement of actin microfilaments and deterioration of ZO-1 structure [9]. Since then, the effect of the zonulin pathway on the regulation of intestinal permeability has been supported by phase 2 clinical studies demonstrating the beneficial effect of the zonulin antagonist larazotide acetate (AT-1001) in patients with celiac disease [10]. Although the most of our knowledge about zonulin is related to intestinal diseases, its importance in almost all our organs, including brain, heart, lung, kidney, liver, skin, etc., has now been described [11,12,13,14,15,16,17]. Indeed, dysbiosis is associated with increased intestinal zonulin release, impaired gut permeability, and upregulation of inflammatory mediators. The spread of gut-derived microbial fragments, toxins, and inflammatory factors, including zonulin, finally reach distant organs, including the central nervous system, leading to increased blood–brain barrier (BBB) permeability, neuroinflammation, and behavioral changes that are partially ameliorated by microbiota depletion [18]. All these together suggest that dysbiosis and the zonulin pathway may be central factors in MGBA-related diseases.
In this review, we aimed to summarize the latest results about the zonulin pathway, focusing on the regulatory effect of microbiota on zonulin release, the relationship between zonulin and the central nervous system (CNS), and the possible zonulin-related therapeutic opportunities targeting TJs, in particular ZO-1. Due to the similar appellations of ZO-1, Zot, and zonulin, these molecules are often confused in the literature. Therefore, as a part of this article, we try to draw attention to the misunderstandings arising from imprecise wording, as well the known technical issues and limitations of zonulin-related research. Our review processes a wide variety of literary data, including clinical observations, clinical trials, in vitro, and in vivo experimental data; therefore, we hope that it will prove useful to those involved in translational research on zonulin and MGBA.

2. Zonulin

2.1. Zonulin as Pre-Haptoglobin 2

In the 1990s, a novel toxin secreted by Vibrio cholera, called Zot or zonula occludens toxin, was described. Zot interacts with its specific cell surface receptor present in the gut [19] and brain [20] and induces PKC-dependent polymerization of actin microfilaments thereby regulating TJs and increasing the permeability of the epithelial layer [21,22,23,24]. In addition to Vibrio cholerae, other Vibrio strains can produce similar 3D structure proteins, causing cytoskeletal disruption of epithelial cells [25]. Moreover, Campylobacter spp., including Campylobacter concisus, can also release Zot, and although it has only 16% amino acid identity compared to Vibrio cholerae Zot, it still induces intestinal epithelial barrier damage [26,27,28].
In 2000, Wang et al. reported a protein isolated from the human intestine, sharing significant structural and biological similarities with Zot, derived from Vibrio cholerae, it was therefore named zonulin [11]. In this study, zonulin was purified from mucosal lysates using anti-Zot antibody affinity columns, and it was demonstrated that the exposure of intestinal tissue to zonulin decreases the transepithelial resistance in an Ussing chamber. In the same year, Fasano et al. published their findings on the elevated level of zonulin in the intestinal tissue of patients with active celiac disease [9].
Later, Tripathi et al. demonstrated that zonulin is identical to pre-haptoglobin 2, an inactive precursor of haptoglobin 2 [7]. Haptoglobins are secretory proteins, belonging to the acute-phase plasma proteins [29]. Although a large amount of haptoglobin is present in the serum under physiological conditions, its production is upregulated by major inflammatory cytokines, including IL-1, IL-6, and TNF-α [29,30,31]. The primary function of haptoglobins is to eliminate the hemoglobin released from lysed red blood cells, which could cause tissue damage due to its strong oxidative and proinflammatory effect [32]. Haptoglobins form a stable covalent bond with hemoglobin, thereby stabilizing it in a reduced state and facilitating its binding to CD163 receptor expressed on macrophages, thereby accelerating the clearance of hemoglobin via endocytosis [29].
Haptoglobin has two genetic variants, haptoglobin 1 and 2, resulting in three possible phenotypes (1-1 homozygote, 2-1 heterozygote, and 2-2 homozygote) in humans [33]. Pre-haptoglobin 2 is the primary translation product of the haptoglobin 2 mRNA, found in individuals with heterozygous or homozygous haptoglobin 2 genotypes [7,34,35]. The pre-haptoglobin 2 goes through a complex maturation process to reach its active form, including proteolytic cleavage in the endoplasmic reticulum, formation of disulphide bonds, dimerization, and other post-translational modifications, such as glycosylation, acetylation, iodination, or nitration [31,33]. In this process, the cleavage enzyme protease complement C1r subcomponent-like protein (C1r-LP) plays a crucial role [36,37,38], and thus is also hypothesized by Fasano to modulate the amount of zonulin in the circulation [39]. Serum level of pre-haptoglobin 2 or zonulin is approximately one thousandth of mature haptoglobins [7] and do not form complexes with hemoglobin [36,40].

2.2. Regulation of Zonulin

The liver is known as the major source of haptoglobins and C1r-LP; however, intestinal mucosal biopsies, organoids, and epithelial cell cultures have shown that large amounts of zonulin can also be released from the intestine [9,11,41,42].
The main regulator of zonulin release in the gut is C-X-C chemokine receptor type 3 (CXCR3) [42,43], which is an inflammatory chemokine receptor, characterized by a versatile ligand profile, including members of the interferon-γ-induced C-X-C motif chemokine ligand (CXCL) family. The primary role of CXCR3 is to induce chemotaxis, cell migration, and adhesion of immune cells [44,45]. Recently, CXCR3 has also been shown to be present in the intestinal lamina propria and epithelial cells, and its expression is upregulated in the inflamed intestine of patients with celiac or inflammatory bowel diseases [43,46,47]. In addition, luminal agents, including microbial and nutritional components (which represent important members of the MGBA) can also activate CXCR3-dependent zonulin release [48]. Indeed, using CXCR3 knock-out mice and various ex vivo and in vitro models, Lammers et al. demonstrated that CXCR3 activation by gliadin fragments led to myeloid differentiation primary response 88 (MyD88)-dependent zonulin release from intestinal epithelial cells [43,49]. MyD88 is an intracellular adaptor molecule for cell surface receptors such as Toll-like receptors (TLRs) and interleukin 1 receptors, and its primary role is to induce transcription by nuclear translocation of transcription factors, including interleukin regulatory factor (IRF) proteins and nuclear factor-κB (NF-κB) [50]. Although the gliadin-induced zonulin release has been found to be associated with celiac disease, the harmful effects of gluten exposition on intestinal epithelial cell viability and permeability have also been described in non-celiac patients [6,51]. Therefore, understanding the complex role of zonulin may also contribute to the development of therapy against other diseases. Disorders associated with abnormal zonulin levels will be discussed later in Section 3. Zonulin-related diseases.
Recently, the pivotal impact of microbiota on zonulin release has also been described; however, the underlying mechanism is partly unclear. Several studies have shown that bacterial lipopolysaccharide (LPS), derived from Escherichia coli, induces zonulin release in CaCo2 colon epithelial cells [52], whereas Thomas et al. found no effect on macrophages [49]. In addition, work by others has shown that treatment with LPS can also increase the expression of CXCR3 in epithelial and endothelial cells in vitro and in vivo [53,54]. Zhang et al. proved on CXCR3 knock-out mice that LPS-induced intestinal dysfunction and barrier damage is a CXCR3-dependent mechanism related to the NF-κB signalling pathway [55]. Lauxmann et al. drew attention to the structural similarity between gliadin fragments and certain parasite proteins and showed that the polyQ sequences of coccidian proteins can bind to the intestinal CXCR3 receptor, leading to an increase in intestinal permeability, thereby promoting parasite invasion into the lamina propria [56]. Indeed, the possible connection between zonulin and parasitic infections, such as malaria, was suggested by genetic studies, demonstrating an increased allele frequency in disease population [57]. Moreover, another study reported that elevated fecal zonulin levels were associated with fungal and parasitic overgrowth in stool samples [58]. These preliminary findings suggest that zonulin may play a role in parasitic infections.
Nevertheless, the link between gut microbiota and the regulation of zonulin release is unquestionable. Numerous studies have aimed to explore the effect of various species of bacteria (without expressing Zot) on zonulin levels in both descriptive (Table 1) and interventional (Table 2) human studies.
Related findings from experimental studies on cell lines and animal models are summarized in Table 3. Briefly, several Gram-negative bacterial strains, including Escherichia coli, Prevotella, Pseudomonas, and Salmonella spp., induce intestinal zonulin release, whereas others, mostly Gram-positive strains, such as Bifidobacterium and Lactobacillus spp., decrease zonulin levels (figure in Section 6). A possible mechanism underlying the protective effects of Bifidobacterium and Lactobacillus spp. is that these bacteria can cleave gluten peptides via hydrolyzing enzymes, thereby inhibiting the gliadin-induced cytotoxic responses in intestinal epithelial cells [87,88,89]. The presence of an additional pathway is suggested by recent findings demonstrating that heat-killed Bifidobacterium [90] and Lactobacillus [91] spp. (which do not produce active enzymes) still have beneficial effects on epithelial barrier function.
However, the therapeutic applicability of protective bacteria was proved in a few clinical studies, although further research is needed to reveal the most promising bacterial strains and to develop effective medical products containing the optimal mixture of probiotics and prebiotics.

2.3. Biological Activity of Zonulin

Tripathi et al. found that zonulin contains an epidermal growth factor (EGF)-like and also a proteinase-activated receptor 2 (PAR2) activating peptide-like motif, both necessary to activate EGFR [7]. Indeed, zonulin has been shown to fail to induce EGFR phosphorylation in PAR2 knock-down cells or knock-out mice, suggesting the importance of PAR2-induced transactivation of EGFR.
Since then, several studies have shown that crosstalk between EGFR and PAR2 via Ras-MAP-kinase pathway has a major impact on epithelial processes [109,110,111]. During its maturation, proteolytically cleaved zonulin (pre-haptoglobin 2) loses its EGFR activating capacity and does not increase intestinal permeability; however, it gains a new property for hemoglobin binding (see above in Section 2.1. Zonulin as pre-haptoglobin 2) [7].
Besides the transactivation of EGFR, PAR2-activation induces phosphatidyl inositol (PPI) turnover and stimulation of phospholipase C leading to diacylglycerol (DAG) activation and intracellular Ca2+ release through inositol 1,4,5-triphosphate (IP-3) increment, both of which induce PKC activation [112,113,114]. PKC activation causes depolymerisation and reduced peripheral density of the actin fibers, leading to cytoskeletal rearrangement and phosphorylation of ZO-1, causing its dislocation from the cell membrane [23,115,116,117]. As ZO-1 and actin fibers have a pivotal role in the maintenance of cell–cell adhesion of epithelial and endothelial cells, these processes lead to transient disassembly of the tight-junction complex and thus an increase in paracellular permeability [7,8,115,118,119] (figure in Section 6).
Interestingly, whereas zonulin-independent activation of PAR2 resulted in zonulin-like effects on the epithelial layer, leading to a decrease in transepithelial resistance (TER) and ZO-1 translocation [120,121,122], activation of EGFR by recombinant EGF had a protective effect on paracellular permeability and TJ integrity [123,124]. However, PAR2-mediated EGFR activation by house dust mite leads to decreased resistance and TJ disruption in bronchial epithelial cells [111]. Similarly, contradictory results have been obtained from studies using PAR2 or EGFR modulator compounds. These data are discussed later in Section 4.4. Other receptor modulators.

3. Diseases Associated with Altered Zonulin Levels

Most of our knowledge of the zonulin pathway is derived from research on gluten-sensitive enteropathy, also known as celiac disease [125]. Exposure to intestinal bacterial components or gliadin has been shown to lead to increased zonulin release, intestinal permeability, and consequently exacerbation of worsening clinical symptoms in patients with celiac disease [7,9,11]. Recent studies have proved that intestinal zonulin plays a crucial role in the pathomechanism of other gastrointestinal diseases [8,42]. Elevated zonulin levels, associated with impaired mucosal barrier functions, have been described in non-celiac gluten sensitivity (NCGD) [126], irritable bowel syndrome (IBS) [127,128], inflammatory bowel diseases (IBD) [34,46,129], necrotizing enterocolitis [130], neonatal gastrointestinal abnormalities [75,131], and environmental enteric dysfunction [132,133].
In addition to intestinal diseases, numerous studies have reported increased zonulin levels in various liver diseases, including non-alcoholic fatty liver disease, hepatitis, cirrhosis, and hepatocellular carcinoma [14,134,135,136]. In a recent systematic review, Ghanadi et al., analyzing the related literature, concluded that elevated levels of zonulin may lead to the release of pathogens, antigens, and toxic metals from the intestine to the liver, thereby triggering inflammatory responses and subsequent liver tissue damage [14].
A remarkable body of evidence links the zonulin-induced loss in small intestinal barrier function with diabetes mellitus, as elevated serum or fecal zonulin levels may predict the onset of the disease and shows correlation with poor glycaemic control in type 1 (T1D) [137,138,139] and type 2 (T2D) diabetes patients [69,140]. The association between zonulin levels and impaired glucose metabolism has also been described in patients with obesity [62,141,142,143,144] or insulin resistance associated with polycystic ovary syndrome (PCOS) [145,146]. Moreover, it has recently been shown that elevated levels of zonulin could be a potential predictor of complications related to pregnancy, including gestational diabetes (GDM), intrahepatic cholestasis (ICP), hypertensive disorders (HDP), and adverse perinatal outcomes [131,147,148,149,150,151,152].
Similarly, increased intestinal permeability and elevated zonulin levels have been described in patients with various forms of arthritis, including rheumatoid arthritis (RA), ankylosing spondylitis, or spondyloarthropathy [59,153,154,155]. These studies suggest that the integrity of intestinal barrier may determine the severity of systemic inflammation due to the migration of immune cells from the gut into the joints [153]. In addition, a possible role of zonulin in the pathomechanism of other disorders has been suggested, including but not limited to cardiac [68,156], pulmonary [12,13,157,158], or renal diseases [15,159,160,161].

3.1. Central Nervous System Diseases

Emerging literary data over the past decades have revealed the link between the presence of dysbiosis, gastrointestinal disorders, and an increased risk of diseases affecting the central nervous system. Not surprisingly, a growing body of research has demonstrated the possible role of zonulin in the pathomechanism of these MGBA diseases.
High serum zonulin levels and impaired intestinal barrier functions have been reported in pediatric patients with mental disorders, including attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) [162,163]. In addition, positive correlation has been found between zonulin levels and the severity of autism as quantified by Childhood Autism Rating Scale (CARS) scores [164,165].
Similarly, elevated zonulin release has been found in adult patients with CNS diseases, including bipolar disorder [166], schizophrenia [167], anxiety, depression [73,168], Alzheimer’s disease [169], Parkinson’s disease [170], or sclerosis multiplex [171]. Most of these studies have shown that zonulin levels are associated with disease progression.
The intact BBB plays a crucial role in the protection of central neurons by regulating the penetration of circulating antigens, immune cells, inflammatory agents, toxins, and pathogens [172]. Previously, Rahman et al. have shown that brain endothelial cells express zonulin receptors, including EGFR and PAR2, and that the exposure of BBB to zonulin leads to its increased permeability [173]. As we described above (Section 2.2 Biological activity of zonulin), activation of zonulin receptors leads to the disruption of actin cytoskeleton and to the dislocation of ZO-1, causing the deterioration of the TJ complex. Claudin-5 is the most enriched member of TJ proteins in the BBB, and its integrity is crucial for neuroprotection [174]. Several studies have shown that increased intestinal zonulin release and permeability are associated with high serum levels of claudin-5 in patients with neuroinflammatory or neurodegenerative disorders [73,166,167,175,176].
Recently, Miranda-Ribera et al. have demonstrated a key role of the zonulin pathway in CNS diseases using a zonulin transgenic mouse strain [18]. It has been shown that high levels of zonulin resulted in increased intestinal permeability of mice and dysbiosis as a consequence of the malabsorption-related changes of luminal content. In addition, zonulin transgenic mice were characterised by impaired BBB integrity, neuroinflammation, and behavioral alterations, which were moderately ameliorated by antibiotic treatment, causing microbiota depletion in their gut.
Stuart et al. published their results on the role of zonulin in BBB integrity in a short Letter to editor, suggesting that zonulin may regulate the pathophysiological processes in neurological diseases indirectly, through the regulation of the gut–brain axis. The author did not demonstrate a direct effect of zonulin treatment on the permeability of cerebral microvascular endothelial cells [35], which contradicts the previous findings of Rahman et al. [173]. A possible explanation could be that these studies used different recombinant zonulins, but it is more likely that the reason for the different findings is the applied dose of zonulin. Indeed, Tripathi et al. demonstrated that zonulin (which was identical to Stuart’s) at concentrations of 40–200 μg/mL increased intestinal permeability in mice, but a concentration of 20 μg/mL or lower had no effect on permeability [7]. Stuart et al. used a single zonulin treatment of 15 μg/mL, which probably was too low to affect the permeability of endothelial cells.

3.2. Viral Infections

Partly due to the intensified research on the SARS-CoV-2 pandemic, emerging data have recently revealed the role of the zonulin pathway in viral infections, which, in addition, often have CNS involvement. Elevated zonulin levels were demonstrated in patients with SARS-CoV-2 infection, which was associated with more severe outcomes [175,177,178,179,180,181]. These studies suggest that the prolonged presence of undigested SARS-CoV-2 viruses leads to enhanced zonulin release in the gastrointestinal tract, resulting in impaired intestinal permeability, which goes together with the accelerated trafficking of viral antigens into the bloodstream, leading to hyperinflammation (causing multisystem inflammatory syndrome—MIS). Moreover, a high serum level of zonulin leads to the disruption of BBB allowing viruses to penetrate into the brain and cause severe neurological symptoms as well [178,180].
Accordingly, similar findings have been demonstrated in connection with the human immunodeficiency virus (HIV), showing the connection between elevated serum zonulin levels and worsening gastrointestinal symptoms or decreased liver function [182,183,184].
Increased zonulin levels were also reported in patients with hepatitis B virus-associated chronic hepatitis [134]. However, decreased serum zonulin amounts were measured in patients with hepatitis B and C virus infection [185,186], which are somehow contradictory to the substantial amount of literary data on zonulin in different liver diseases [14]. Although the authors gave no explanation for decreased serum zonulin levels, the reason for the observed phenomenon could be a technical issue, which is discussed later in Section 5.2. Technical issues.

4. Zonulin Pathway as a Therapeutic Target

The integrity and thus the function of BBB TJs play a crucial role in the pathomechanism of neuroinflammatory and neurodegenerative diseases. Previously, it has been suggested that targeting different elements of the zonulin pathway, including actin filaments, TJs, or NF-κB, have potential therapeutic effects on CNS diseases. Indeed, encouraging results are accumulating from a recent preclinical study, using myosin light chain kinase (MLCK) inhibitor ML-7, which attenuates BBB disruption by preventing the disintegration of actin cytoskeletal microfilaments [187]. Similarly, blocking the cleavage of TJ proteins by matrix metalloproteases (MMP) inhibitors, using either direct (broad-spectrum or selective MMP-2 and MMP-9) [188,189] or indirect inhibitors (COX) [190] has been shown to protect BBB. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists, such as rosiglitazone, pioglitazone, or D-allose, also prevented BBB integrity by inhibiting NF-κB activation [191,192,193,194]. Therefore, the use of zonulin inhibitors seems to be justified in the treatment of CNS diseases.

4.1. Human Studies with Larazotide Acetate

Over the past decade, larazotide acetate (also known as AT-1001), a pharmacological inhibitor of the zonulin pathway, has received increasing attention. Firstly, Wang et al. published a synthetic oligopeptide (GGVLVQPG) in 2000, representing an N’-terminal sequence of zonulin, which had a strong inhibitory effect on receptor binding of zonulin [11]. Since then, a large amount of knowledge has accumulated on this competitive zonulin inhibitor, demonstrating its strong effect on the regulation of TJs and making it one of the most promising therapeutic candidates for celiac disease [195]. Several interventional human studies have demonstrated good tolerability and beneficial effects of larazotide acetate on intestinal permeability (Table 4).
As larazotide acetate has successfully passed phase I and II clinical trials, the scientific community has raised the opportunity of its expanded access. As discussed above in the Section 3.2. Viral infections, a role for zonulin has been suggested in the pathomechanism of COVID-19-associated complications. Accordingly, short time proof-of-concept studies in a limited number of enrolled patients have shown that treatment with larazotide acetate improves the clinical manifestations of MIS-C by reducing gastrointestinal symptoms and the severity of systemic inflammation (Table 4) [178,210]. Now, its efficacy is under investigation in a phase II, randomized, double-blind, placebo-controlled clinical trial in patients with MIS-C [211]. In addition, the potential use of larazotide acetate in the treatment of metabolic diseases, including insulin resistance, diabetes mellitus, or non-alcoholic fatty liver disease (NAFLD), as well as to improve glucose and lipid metabolism of patients, has been hypothesized [212].

4.2. Preclinical Studies with Larazotide Acetate

Recently, human and basic research studies have revealed that high zonulin levels may affect the permeability of not only the intestine but also of other organs. Therefore, numerous preclinical studies have aimed to investigate the efficacy of larazotide acetate in experimental animal models of various diseases. Briefly, treatment with larazotide acetate has been shown to improve epithelial barrier function, thereby attenuating the severity of the investigated disorders, including colitis, vasculitis, fibrosis, arthritis, and respiratory or liver diseases (Table 5).

4.3. Future Perspectives of Zonulin Antagonists

Larazotide acetate was originally created as an orally administered drug with minimal absorption as the primary target cells were intestinal epithelial cells [195]. The oral administration of a therapeutic peptide can be challenging especially for compounds with expected systemic effect [226]. Systemic drugs have to penetrate the intestinal barriers, including a thick mucus gel and epithelial layer before being digested by luminal enzymes. The phase II clinical trial to evaluate the efficacy and tolerability of larazotide acetate showed that plasma levels were below the quantification limit (0.5 ng/mL) even after 7 or 14 days of daily treatment [198]. Therefore, no systemic effect should be expected after the per os treatment with larazotide acetate. At the same time, as shown in Table 5, summarizing the different methods of administration, intratracheal, intravenous, or intraperitoneal administration of larazotide acetate produced beneficial effects.
The original drug has to undergo further pharmacological development for extraintestinal use. Recent studies have reported that modification of larazotide acetate or its derivates has improved lipophilicity and intestinal absorption [227,228,229]. The resulting compound retained the biological activity of larazotide acetate and was detectable (20–30 ng/mL) in the plasma of mice after a single per os administration [229].
Besides larazotide acetate, there is another synthetic zonulin-related peptide fragment known as AT-1002, which, unlike larazotide acetate (AT-1001), has proved to be an agonist of zonulin receptors. Indeed, treatment of epithelial or endothelial cells with AT-1002 led to increased permeability by reversible opening of TJs [230,231]. Since its discovery, AT-1002 has become an important permeability-modulating component in drug development that can be used to increase the absorption and distribution of other drugs [230,232]. Several studies showed that AT-1002 can be used to increase intestinal, intranasal, intratracheal, or transdermal penetration of various compounds improving their bioavailability [233].
These preclinical data suggest that larazotide acetate or other zonulin receptor modulators (by choosing the appropriate route of administration) may prevent BBB integrity and should be investigated in CNS-related diseases, as well.

4.4. Other Receptor Modulators

Although binding to zonulin receptors, including PAR2 and EGFR, leads to the disruption of TJs, literary data on modulation of PAR2 and EGFR by inhibitors other than larazotide acetate are confusing (Table 6).
Recently, it has been shown that, in contrast to larazotide acetate, peptidic antagonists of PAR2, including FSLLRY-NH2 or SLIGRL-NH2, decreased the expression of ZO-1 and claudin-1 and destroyed the barrier function of nasal epithelial cells [121]. Similarly, a small molecule antagonist, GB83, exerted harmful effects on colon epithelial cells by decreasing the expression of autophagy- and TJ-related factors and increased permeability [234]. In contrast, inhibition of the PAR2 pathway by GB88 in lung epithelial cells [235] or using I-191 in arterial endothelial cells [236] moderated actin rearrangement and TJ disruption and reduced the permeability of the cellular monolayers. Moreover, a non-peptidic PAR2 ligand, the full agonist AC-55541, ameliorated the IL-17-induced loss of epithelial resistance in brain microvascular endothelial cells [237].
The EGFR tyrosine kinase inhibitor AG1478 also prevented TJ disassembly and epithelial resistance impairment in microvascular endothelial cells modeling BBB [238], in lung epithelial-like cells [239], and in oral epithelial tumour cells [240]. In contrast, decreased expression of TJs, barrier dysfunction, and increased permeability were induced by other EGFR tyrosine kinase inhibitors, such as erlotinib [241], gefitinib, icotinib [242], or dacomitinib [243,244] in intestinal epithelial cells. Similar effects were found in other cell types after treatment with lapatinib [245] or vandetanib [246]. These studies suggest that these compounds have a significant impact on the complex signaling pathway of EGFR, triggering stress responses, and finally leading to cell death [242]. This phenomenon may be the underlying molecular mechanism of diarrhea, which is one of the most frequent side effects of second-generation EGFR inhibitors [247].
All these data together suggest that PAR2 or EGFR modulators could be used to regulate epithelial or endothelial barrier function, considering that the applied drug should affect the PPI-DAG-PKC pathway, which plays a central role in zonulin-induced TJ disruption, but not ERK, JNK, or Akt signaling, which are essential for the physiological regulation of basic cellular processes, including cell growth, survival, proliferation, and apoptosis [248].
Table
Table 6. Effect of PAR2 and EGFR modulators on TJ integrity and/or transcellular permeability of epithelial or endothelial cells based on literary data.
Table 6. Effect of PAR2 and EGFR modulators on TJ integrity and/or transcellular permeability of epithelial or endothelial cells based on literary data.
TargetTypeCompoundCell LineEffect on TJs and/or
Transcellular Permeability		Ref.
PAR2peptidic antagonistFSLLRY-NH2pHNECsharmful[121]
SLIGRL-NH2
non-peptidic full agonistAC-55541hBMECsprotective[237]
small molecule antagonistGB88A549[235]
hECs[236]
GB83Caco2harmful[234]
EGFRtyrosine kinase inhibitorAG1478hCMEC/D3protective[238]
Calu-3[239]
HSC-3[240]
erlotinibIEC-6harmful[241]
gefitinib[242]
icotinib
dacomitinibT84[244]
lapatinibHBCCs[245]
vandetanibCalu-6[246]
Abbreviations: pHNECs: primary human nasal epithelial cells; hBMECs: human brain microvascular endothelial cells; hECS: primary human arterial endothelial cells; hCMEC: primary human cardiac microvascular endothelial cells; HBBCs: primary human breast cancer epithelial cells.

5. Considerations

5.1. Nomenclature

During the preparation of the present review, several anomalies were identified in the literature on zonulin. Some of them stemmed from the incorrect use of the zonulin-related nomenclature. Indeed, at some point in writing the present manuscript, a Google Scholar search gave 74 hits using “zonulin (ZO-1” as a search term, implying that at least these studies considered the two different proteins to be identical. What is even more astonishing is that the amount of zonulin as a biomarker was investigated in many of these articles [69,90,108,176,249]. As discussed above (in Section 2.2 Biological activity of zonulin), zonulin and ZO-1 are related. Zonulin is a secreted protein, which binds to its receptors to induce cytoskeletal reorganisation and TJ disruption. ZO-1 is a member of the TJ system responsible for the cross-linking of transmembrane TJ proteins (e.g., claudin, occludin) with the actin cytoskeleton. Overall, zonulin and ZO-1 are not identical—ZO-1 is more of a target of zonulin, which explains why the expression of these proteins usually changes in opposite ways (Table 3).
Similarly, numerous studies use the appellation ‘zonulin-1’ (595 hits in Google Scholar), which is a non-existing protein, but a mixture of the denominations of zonulin and zonula occludens 1 [14,69,89]. It can be assumed that the biological interpretation of the findings from these studies is questionable, or at least confusing.
Similarly, the synonymy of larazotide acetate may be a source of confusion, as other compounds are also known as AT-1001. Indeed, migalastat hydrochloride (Galafold), a pharmacological chaperone drug approved by FDA for Fabry disease is also referred to as AT-1001 in clinical trials [250,251]. Moreover, AT-1001 is also a synonym for an α3β4 nicotinic acetylcholine receptor antagonist, a potential therapeutic agent for smoking cessation [252].

5.2. Technical Issues: Zonulin as a Biomarker and Therapeutic Target

Much of our knowledge on zonulin is due to the work of Fasano and his colleagues, including the effect of Zot derived from Vibrio cholerae on intestinal permeability, the discovery of its human analogue zonulin, the identification as pre-haptoglobin 2, the description of the regulation of zonulin release, the exploration of the underlying molecular mechanisms, and biological outcomes of zonulin receptor activation. These studies and their findings are reasonably coherent and follow a logical path; however, some results may not be sufficiently supported by independent experiments. This is perhaps one possible reason for the increasing number of controversies about zonulin in recent years.
Over the past decade, several studies have examined serum zonulin levels in various diseases, and along with that, many of these publications have demonstrated that zonulin cannot be used as a biomarker of increased intestinal permeability [253,254,255,256]. Emerging evidence has revealed that the controversial results of these studies may be due to some commercially available enzyme-linked immunosorbent assays (ELISAs) to specifically detect zonulin [93,257,258,259,260].
These issues led to a series of short PostScript publications on the pages of Gut, a prestigious journal of gastroenterology. Massier et al. explained that the controversial results of commercial ELISAs may be due the fact that the first published sequence of zonulin, against which the ELISAs were developed, does not cover all different zonulin sequences [261]. This is supported by the fact that the sequence of proteins isolated with anti-Zot antibodies and identified as zonulin by Fasano et al. [7,11] does not contain the octapeptide sequence of larazotide acetate, which was initially used as a zonulin receptor antagonist [262]. The peptide fragment in question is rather an immunoglobulin sequence, which can be easily confirmed by a protein query using NCBI Protein BLAST. In addition, Massier et al. point out that the measurement of zonulin levels in preclinical studies is highly questionable, as pre-haptoglobin-2 is a human-specific protein and is not naturally expressed in rodents [261].
In his reply, Fasano provided some clarifications [263]. Briefly, the author pointed out that zonulin is rather a family of structurally and functionally related proteins (zonulin family peptides—ZFPs), including not only pre-haptoglobin-2 but also other mannose-binding lectin-associated serine proteases (MASPs), such as properdin, coagulation factor X, or CD5 antigen [264]. Indeed, in recent years, an increasing number of studies have introduced the expression of ZFP or zonulin-related protein (ZRP) instead of zonulin or pre-haptoglobin-2 [144,257,259,265]. Fasano concluded that despite the possible non-specificity of commercial ELISAs, which should be clarified to improve their reliability, the overall impact of the zonulin pathway on diseases associated with altered tissue permeability is unequivocal. This perspective is consistent with the fact that zonulin or related proteins (ZRPs, ZFPs) have been detected in human patients with haptoglobin 1-1 homozygous genotype [35] and in various rodents (Table 3), which have been shown not to express pre-haptoglobin-2. Moreover, treatment with zonulin receptor antagonist larazotide acetate has also shown a protective effect in numerous preclinical studies in non-humanized mice or rats as well (Table 5).
Choosing the appropriate zonulin ELISA kit is a challenge. The most commonly used kit, manufactured by Cusabio, was developed to detect pre-haptoglobin-2, but its cross-reactivity with properdin, pre-haptoglobin-1, or mature haptoglobins was not investigated. However, the exact protein sequence of the immunogen epitope and that of the standard protein provided to the product is not public. The specificity of Elabscience’s is also questionable as both the full-length recombinant pre-haptoglobin-2, a part of mature haptoglobin sequence, and Vibrio cholerae-derived Zot was assigned as the target of the applied antibody. Immundiagnostik offers an ELISA intended for the determination of ZFPs, based on a polyclonal antibody against zonulin sequence published by Wang [11], which, as discussed above, was isolated by anti-Zot antibodies and does not overlap with the known sequence of pre-haptoglobin-2. Clarifying these issues is essential for the proper interpretation of measured data, and in addition, may clarify the possible role of other ZFP members in the pathomechanism of various diseases.

6. Summary

In the present article, we summarized recent literary data on the potential role of zonulin and its receptors in the MGBA-related diseases (Figure 1).
Luminal agents, including gliadin and microbiota components, may induce zonulin release from the intestinal epithelial cells through CXCR3 receptor activation. It has been shown that while Gram-negative bacteria mostly facilitate this process, some bacterial strains, including Bifidobacterium and Lactobacillus spp. decrease intestinal zonulin production.
Free zonulin binds to its cell surface receptors, EGFR and PAR2, leading to cytoskeletal rearrangement and TJ-disassembly of epithelial cells causing increased intestinal permeability. Consequently, the impaired intestinal barrier facilitates the penetration of luminal agents and promotes intestinal inflammation. The immunogenic substances and proinflammatory cytokines may also enter the bloodstream, affecting BBB and other tissues. Brain endothelial cells also express zonulin receptors, thereby the circulating zonulin can directly increase the permeability of BBB, facilitating neuroinflammation. This process may explain the observation that CNS diseases are often associated with dysbiosis and increased serum zonulin levels, which correlate with the deterioration of cognitive functions.
Several promising studies have shown that intestinal permeability can be normalized pharmacologically by modulating zonulin receptors, such as larazotide acetate. In addition to preserving the function of the intestinal barrier and thereby reducing the levels of proinflammatory factors in the blood (which may have a neuroprotective effect in itself), zonulin-antagonists, PAR2 modulators, or EGFR inhibitors may be useful tools to reduce neuroinflammation by acting directly on the endothelial cells of BBB.
Although there are pharmaceutical challenges and technical issues to be solved, our knowledge of zonulin suggests that it may play a crucial role both in intestinal and CNS diseases and may serve as a potential therapeutic target.

Author Contributions

Conceptualization, A.V.-S. and Á.V.; literature search: A.V.-S. and C.S.; writing—original draft preparation: A.V.-S. and Á.V., writing—review and editing: D.P., B.S. and P.B., visualization: A.V.-S. and P.B. All authors have read and agreed to the published version of the manuscript.

Funding

This research was founded by the National Research, Development and Innovation Office (NKFIH) K-142728; Semmelweis University, TKP2021-EGA-24, STIA-KFI-2021; Eötvös Loránd Research Network, ELKH-POC-2022-024; the New National Excellence Program of the Ministry for Culture and Innovation from the Source of the National Research, Development and Innovation Fund, ÚNKP-22-4-II-SE-12, ÚNKP-22-5-SE-17; Hungarian Academic of Sciences, János Bolyai Research Scholarship.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare that they have no conflict of interest.

References

  1. Cryan, J.F.; O’Riordan, K.J.; Cowan, C.S.; Sandhu, K.V.; Bastiaanssen, T.F.; Boehme, M.; Codagnone, M.G.; Cussotto, S.; Fulling, C.; Golubeva, A.V. The microbiota-gut-brain axis. Physiol. Rev. 2019, 99, 1877–2013. [Google Scholar] [CrossRef] [PubMed]
  2. Oriach, C.S.; Robertson, R.C.; Stanton, C.; Cryan, J.F.; Dinan, T.G. Food for thought: The role of nutrition in the microbiota-gut–brain axis. Clin. Nutr. Exp. 2016, 6, 25–38. [Google Scholar] [CrossRef]
  3. Morais, L.H.; Schreiber, H.L., IV; Mazmanian, S.K. The gut microbiota–brain axis in behaviour and brain disorders. Nat. Rev. Microbiol. 2021, 19, 241–255. [Google Scholar] [CrossRef] [PubMed]
  4. Pap, D.; Veres-Székely, A.; Szebeni, B.; Vannay, Á. PARK7/DJ-1 as a Therapeutic Target in Gut-Brain Axis Diseases. Int. J. Mol. Sci. 2022, 23, 6626. [Google Scholar] [CrossRef]
  5. Bischoff, S.C.; Barbara, G.; Buurman, W.; Ockhuizen, T.; Schulzke, J.-D.; Serino, M.; Tilg, H.; Watson, A.; Wells, J.M. Intestinal permeability—A new target for disease prevention and therapy. BMC Gastroenterol. 2014, 14, 189. [Google Scholar] [CrossRef]
  6. Camilleri, M. Leaky gut: Mechanisms, measurement and clinical implications in humans. Gut 2019, 68, 1516–1526. [Google Scholar] [CrossRef]
  7. Tripathi, A.; Lammers, K.M.; Goldblum, S.; Shea-Donohue, T.; Netzel-Arnett, S.; Buzza, M.S.; Antalis, T.M.; Vogel, S.N.; Zhao, A.; Yang, S. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc. Natl. Acad. Sci. USA 2009, 106, 16799–16804. [Google Scholar] [CrossRef]
  8. Sturgeon, C.; Fasano, A. Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases. Tissue Barriers 2016, 4, e1251384. [Google Scholar] [CrossRef]
  9. Fasano, A.; Not, T.; Wang, W.; Uzzau, S.; Berti, I.; Tommasini, A.; Goldblum, S.E. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet 2000, 355, 1518–1519. [Google Scholar] [CrossRef]
  10. Hoilat, G.J.; Altowairqi, A.K.; Ayas, M.F.; Alhaddab, N.T.; Alnujaidi, R.A.; Alharbi, H.A.; Alyahyawi, N.; Kamal, A.; Alhabeeb, H.; Albazee, E.; et al. Larazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials. Clin. Res. Hepatol. Gastroenterol. 2022, 46, 101782. [Google Scholar] [CrossRef]
  11. Wang, W.; Uzzau, S.; Goldblum, S.E.; Fasano, A. Human zonulin, a potential modulator of intestinal tight junctions. J. Cell Sci. 2000, 113, 4435–4440. [Google Scholar] [CrossRef] [PubMed]
  12. Rittirsch, D.; Flierl, M.A.; Nadeau, B.A.; Day, D.E.; Huber-Lang, M.S.; Grailer, J.J.; Zetoune, F.S.; Andjelkovic, A.V.; Fasano, A.; Ward, P.A. Zonulin as prehaptoglobin2 regulates lung permeability and activates the complement system. Am. J. Physiol. Cell Mol. Physiol. 2013, 304, L863–L872. [Google Scholar] [CrossRef] [PubMed]
  13. Rittirsch, D.; Flierl, M.A.; Day, D.E.; Nadeau, B.A.; Werner, C.M.L.; Wanner, G.A.; Simmen, H.; Fasano, A.; Ward, P.A. Role of zonulin as prehaptoglobin2 in acute lung injury. FASEB J. 2011, 25, 114.1. [Google Scholar] [CrossRef]
  14. Ghanadi, K.; Naghdi, N. The Role of Zonulin as a Prognostic Biomarker in Liver Diseases: A Systematic Review. Adv. Life Sci. 2022, 9, 277–283. [Google Scholar]
  15. Yu, J.; Shen, Y.; Zhou, N. Advances in the role and mechanism of zonulin pathway in kidney diseases. Int. Urol. Nephrol. 2021, 53, 2081–2088. [Google Scholar] [CrossRef] [PubMed]
  16. Smecuol, E.; Sugai, E.; Niveloni, S.; Vázquez, H.; Pedreira, S.; Mazure, R.; Moreno, M.L.; Label, M.; Mauriño, E.; Fasano, A. Permeability, zonulin production, and enteropathy in dermatitis herpetiformis. Clin. Gastroenterol. Hepatol. 2005, 3, 335–341. [Google Scholar] [CrossRef] [PubMed]
  17. Sheen, Y.; Jee, H.; Kim, D.; Ha, E.; Jeong, I.; Lee, S.; Baek, H.; Lee, S.; Lee, K.; Lee, K. Serum zonulin is associated with presence and severity of atopic dermatitis in children, independent of total IgE and eosinophil. Clin. Exp. Allergy J. Br. Soc. Allergy Clin. Immunol. 2018, 48, 1059–1062. [Google Scholar] [CrossRef]
  18. Miranda-Ribera, A.; Serena, G.; Liu, J.; Fasano, A.; Kingsbury, M.A.; Fiorentino, M.R. The Zonulin-transgenic mouse displays behavioral alterations ameliorated via depletion of the gut microbiota. Tissue Barriers 2022, 10, 2000299. [Google Scholar] [CrossRef]
  19. Uzzau, S.; Lu, R.; Wang, W.; Fiore, C.; Fasano, A. Purification and preliminary characterization of the zonula occludens toxin receptor from human (CaCo2) and murine (IEC6) intestinal cell lines. FEMS Microbiol. Lett. 2001, 194, 1–5. [Google Scholar] [CrossRef]
  20. Lu, R.; Wang, W.; Uzzau, S.; Vigorito, R.; Zielke, H.R.; Fasano, A. Affinity Purification and Partial Characterization of the Zonulin/Zonula Occludens Toxin (Zot) Receptor from Human Brain. J. Neurochem. 2001, 74, 320–326. [Google Scholar] [CrossRef]
  21. Fasano, A.; Baudry, B.; Pumplin, D.W.; Wasserman, S.S.; Tall, B.D.; Ketley, J.M.; Kaper, J. Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions. Proc. Natl. Acad. Sci. USA 1991, 88, 5242–5246. [Google Scholar] [CrossRef] [PubMed]
  22. Baudry, B.; Fasano, A.; Ketley, J.; Kaper, J.B. Cloning of a gene (zot) encoding a new toxin produced by Vibrio cholerae. Infect. Immun. 1992, 60, 428–434. [Google Scholar] [CrossRef] [PubMed]
  23. Fasano, A.; Fiorentini, C.; Donelli, G.; Uzzau, S.; Kaper, J.; Margaretten, K.; Ding, X.; Guandalini, S.; Comstock, L.; Goldblum, S.E. Zonula occludens toxin modulates tight junctions through protein kinase C-dependent actin reorganization, in vitro. J. Clin. Investig. 1995, 96, 710–720. [Google Scholar] [CrossRef] [PubMed]
  24. Fasano, A.; Uzzau, S.; Fiore, C.; Margaretten, K. The enterotoxic effect of zonula occludens toxin on rabbit small intestine involves the paracellular pathway. Gastroenterology 1997, 112, 839–846. [Google Scholar] [CrossRef]
  25. Pérez-Reytor, D.; Pavón, A.; Lopez-Joven, C.; Ramírez-Araya, S.; Peña-Varas, C.; Plaza, N.; Alegría-Arcos, M.; Corsini, G.; Jaña, V.; Pavez, L.; et al. Analysis of the Zonula occludens Toxin Found in the Genome of the Chilean Non-toxigenic Vibrio parahaemolyticus Strain PMC53.7. Front. Cell Infect. Microbiol. 2020, 10, 482. [Google Scholar] [CrossRef]
  26. Mahendran, V.; Liu, F.; Riordan, S.M.; Grimm, M.C.; Tanaka, M.M.; Zhang, L. Examination of the effects of Campylobacter concisus zonula occludens toxin on intestinal epithelial cells and macrophages. Gut Pathog. 2016, 8, 18. [Google Scholar] [CrossRef]
  27. Zhang, L.; Lee, H.; Grimm, M.C.; Riordan, S.M.; Day, A.S.; Lemberg, D.A. Campylobacter concisus and inflammatory bowel disease. World J.Gastroenterol. WJG 2014, 20, 1259. [Google Scholar] [CrossRef]
  28. Liu, F.; Lee, H.; Lan, R.; Zhang, L. Zonula occludens toxins and their prophages in Campylobacter species. Gut Pathog. 2016, 8, 1–11. [Google Scholar] [CrossRef]
  29. di Masi, A.; De Simone, G.; Ciaccio, C.; D’Orso, S.; Coletta, M.; Ascenzi, P. Haptoglobin: From hemoglobin scavenging to human health. Mol. Asp. Med. 2020, 73, 100851. [Google Scholar] [CrossRef]
  30. Andersen, C.B.F.; Stødkilde, K.; Saederup, K.L.; Kuhlee, A.; Raunser, S.; Graversen, J.H.; Moestrup, S.K. Haptoglobin. Antioxid. Redox Signal. 2017, 26, 814–831. [Google Scholar] [CrossRef]
  31. Sadrzadeh, S.H.; Bozorgmehr, J. Haptoglobin Phenotypes in Health and Disorders. Pathol. Patterns Rev. 2004, 121, S97–S104. [Google Scholar] [CrossRef] [PubMed]
  32. Jelena, A.; Mirjana, M.; Desanka, B.; Svetlana, I.-M.; Aleksandra, U.; Goran, P.; Ilijana, G. Haptoglobin and the inflammatory and oxidative status in experimental diabetic rats: Antioxidant role of haptoglobin. J. Physiol. Biochem. 2013, 69, 45–58. [Google Scholar] [CrossRef] [PubMed]
  33. Naryzny, S.; Legina, O. Haptoglobin as a Biomarker. Biochem. Suppl. Ser. B Biomed. Chem. 2021 15, 184–198. [CrossRef]
  34. Vanuytsel, T.; Vermeire, S.; Cleynen, I. The role of Haptoglobin and its related protein, Zonulin, in inflammatory bowel disease. Tissue Barriers 2013, 1, e27321. [Google Scholar] [CrossRef] [PubMed]
  35. Stuart, C.M.; Varatharaj, A.; Winberg, M.E.; Galea, P.; Larsson, H.B.; Cramer, S.P.; Fasano, A.; Maherally, Z.; Pilkington, G.J.; Keita, Å.V. Zonulin and blood-brain barrier permeability are dissociated in humans. Clin. Transl. Med. 2022, 12, e965. [Google Scholar] [CrossRef] [PubMed]
  36. Schaer, C.A.; Owczarek, C.; Deuel, J.W.; Schauer, S.; Baek, J.H.; Yalamanoglu, A.; Hardy, M.P.; Scotney, P.D.; Schmidt, P.M.; Pelzing, M.; et al. Phenotype-specific recombinant haptoglobin polymers co-expressed with C1r-like protein as optimized hemoglobin-binding therapeutics. BMC Biotechnol. 2018, 18, 15. [Google Scholar] [CrossRef]
  37. Wassler, M.; Fries, E. Proteolytic cleavage of haptoglobin occurs in a subcompartment of the endoplasmic reticulum: Evidence from membrane fusion in vitro. J. Cell Biol. 1993, 123, 285–291. [Google Scholar] [CrossRef]
  38. Wicher, K.B.; Fries, E. Prohaptoglobin is proteolytically cleaved in the endoplasmic reticulum by the complement C1r-like protein. Proc. Natl. Acad. Sci. USA 2004, 101, 14390–14395. [Google Scholar] [CrossRef]
  39. Fasano, A. Zonulin and Its Regulation of Intestinal Barrier Function: The Biological Door to Inflammation, Autoimmunity, and Cancer. Physiol. Rev. 2011, 91, 151–175. [Google Scholar] [CrossRef]
  40. Buzzi, R.M.; Owczarek, C.M.; Akeret, K.; Tester, A.; Pereira, N.; Butcher, R.; Brügger-Verdon, V.; Hardy, M.P.; Illi, M.; Wassmer, A.; et al. Modular Platform for the Development of Recombinant Hemoglobin Scavenger Biotherapeutics. Mol. Pharm. 2021, 18, 3158–3170. [Google Scholar] [CrossRef]
  41. Ligoudistianou, C.; Xu, Y.; Garnier, G.; Circolo, A.; Volanakis, J.E. A novel human complement-related protein, C1r-like protease (C1r-LP), specifically cleaves pro-C1s. Biochem. J. 2005, 387, 165–173. [Google Scholar] [CrossRef] [PubMed]
  42. El Asmar, R.; Panigrahi, P.; Bamford, P.; Berti, I.; Not, T.; Coppa, G.V.; Catassi, C.; Fasano, A. Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure. Gastroenterology 2002, 123, 1607–1615. [Google Scholar] [CrossRef] [PubMed]
  43. Lammers, K.M.; Lu, R.; Brownley, J.; Lu, B.; Gerard, C.; Thomas, K.; Rallabhandi, P.; Shea-Donohue, T.; Tamiz, A.; Alkan, S.; et al. Gliadin Induces an Increase in Intestinal Permeability and Zonulin Release by Binding to the Chemokine Receptor CXCR3. Gastroenterology 2008, 135, 194–204.e3. [Google Scholar] [CrossRef] [PubMed]
  44. Groom, J.R.; Luster, A.D. CXCR3 ligands: Redundant, collaborative and antagonistic functions. Immunol. Cell Biol. 2011, 89, 207–215. [Google Scholar] [CrossRef]
  45. Van Raemdonck, K.; Van den Steen, P.E.; Liekens, S.; Van Damme, J.; Struyf, S. CXCR3 ligands in disease and therapy. Cytokine Growth Factor Rev. 2015, 26, 311–327. [Google Scholar] [CrossRef]
  46. Singh, U.P.; Venkataraman, C.; Singh, R.; Lillard, J.W. CXCR3 axis: Role in inflammatory bowel disease and its therapeutic implication. Endocr. Metab. Immune Disord.-Drug Targets (Former. Curr. Drug Targets-Immune Endocr. Metab. Disord.) 2007, 7, 111–123. [Google Scholar] [CrossRef]
  47. Haghbin, M.; Rostami-Nejad, M.; Forouzesh, F.; Sadeghi, A.; Rostami, K.; Aghamohammadi, E.; Asadzadeh-Aghdaei, H.; Masotti, A.; Zali, M.R. The role of CXCR3 and its ligands CXCL10 and CXCL11 in the pathogenesis of celiac disease. Medicine 2019, 98, e15949. [Google Scholar] [CrossRef]
  48. Heickman, L.K.W.; DeBoer, M.D.; Fasano, A. Zonulin as a potential putative biomarker of risk for shared type 1 diabetes and celiac disease autoimmunity. Diabetes/Metabolism Res. Rev. 2020, 36, e3309. [Google Scholar] [CrossRef]
  49. Thomas, K.E.; Sapone, A.; Fasano, A.; Vogel, S.N. Gliadin Stimulation of Murine Macrophage Inflammatory Gene Expression and Intestinal Permeability Are MyD88-Dependent: Role of the Innate Immune Response in Celiac Disease. J. Immunol. 2006, 176, 2512–2521. [Google Scholar] [CrossRef]
  50. Saikh, K.U. MyD88 and beyond: A perspective on MyD88-targeted therapeutic approach for modulation of host immunity. Immunol. Res. 2021, 69, 117–128. [Google Scholar] [CrossRef]
  51. Uhde, M.; Ajamian, M.; Caio, G.; De Giorgio, R.; Indart, A.; Green, P.H.; Verna, E.C.; Volta, U.; Alaedini, A. Intestinal cell damage and systemic immune activation in individuals reporting sensitivity to wheat in the absence of coeliac disease. Gut 2016, 65, 1930–1937. [Google Scholar] [CrossRef] [PubMed]
  52. Ling, X.; Linglong, P.; Weixia, D.; Hong, W. Protective effects of bifidobacterium on intestinal barrier function in LPS-induced enterocyte barrier injury of caco-2 monolayers and in a rat NEC model. PLoS ONE 2016, 11, e0161635. [Google Scholar] [CrossRef] [PubMed]
  53. Chen, Y.; Zhou, S.; Jiang, Z.; Wang, X.; Liu, Y. Chemokine receptor CXCR3 in turbot (Scophthalmus maximus): Cloning, characterization and its responses to lipopolysaccharide. Fish Physiol. Biochem. 2016, 42, 659–671. [Google Scholar] [CrossRef] [PubMed]
  54. Wang, X.; Zhao, Z.; Zhu, K.; Bao, R.; Meng, Y.; Bian, J.; Wan, X.; Yang, T. Effects of CXCL4/CXCR3 on the lipopolysaccharide-induced injury in human umbilical vein endothelial cells. J. Cell Physiol. 2019, 234, 22378–22385. [Google Scholar] [CrossRef] [PubMed]
  55. Zhang, C.; Deng, Y.; Zhang, Y.; Ba, T.; Niu, S.; Chen, Y.; Gao, Y.; Dai, H. CXCR3 Inhibition Blocks the NF-κB Signaling Pathway by Elevating Autophagy to Ameliorate Lipopolysaccharide-Induced Intestinal Dysfunction in Mice. Cells 2023, 12, 182. [Google Scholar] [CrossRef]
  56. Lauxmann, M.A.; Vazquez, D.S.; Schilbert, H.M.; Neubauer, P.R.; Lammers, K.M.; Dodero, V.I. From celiac disease to coccidia infection and vice-versa: The polyQ peptide CXCR3-interaction axis. Bioessays 2021, 43, e2100101. [Google Scholar] [CrossRef]
  57. Quaye, I.K. Haptoglobin, inflammation and disease. Trans. R. Soc. Trop. Med. Hyg. 2008, 102, 735–742. [Google Scholar] [CrossRef]
  58. El-Doueik, H.; El-Doueik, A. Assessment of the Correlation between Intestinal Permeability, Inflammation and Dysbiosis in Patients with Inflammatory Conditions within a Clinical Setting. 2019; Preprint. [Google Scholar]
  59. Ciccia, F.; Guggino, G.; Rizzo, A.; Alessandro, R.; Luchetti, M.M.; Milling, S.; Saieva, L.; Cypers, H.; Stampone, T.; Di Benedetto, P.; et al. Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis. Ann. Rheum. Dis. 2017, 76, 1123–1132. [Google Scholar] [CrossRef]
  60. Gargari, G.; Mantegazza, G.; Taverniti, V.; Del Bo, C.; Rsquo, C.; Bernardi, S.; Andres-Lacueva, C.; González-Domínguez, R.; Kroon, P.A.; Winterbone, M.S.; et al. Bacterial DNAemia is associated with serum zonulin levels in older subjects. Sci. Rep. 2021, 11, 11054. [Google Scholar] [CrossRef]
  61. Jendraszak, M.; Gałęcka, M.; Kotwicka, M.; Schwiertz, A.; Regdos, A.; Pazgrat-Patan, M.; Andrusiewicz, M.J.B. Impact of Biometric Patient Data, Probiotic Supplementation, and Selected Gut Microorganisms on Calprotectin, Zonulin, and sIgA Concentrations in the Stool of Adults Aged 18–74 Years. Biomolecules 2022, 12, 1781. [Google Scholar] [CrossRef]
  62. Żak-Gołąb, A.; Kocełak, P.; Aptekorz, M.; Zientara, M.; Juszczyk, Ł.; Martirosian, G.; Chudek, J.; Olszanecka-Glinianowicz, M. Gut Microbiota, Microinflammation, Metabolic Profile, and Zonulin Concentration in Obese and Normal Weight Subjects. Int. J. Endocrinol. 2013, 2013, 674106. [Google Scholar] [CrossRef] [PubMed]
  63. Cayres, L.C.d.F.; de Salis, L.V.V.; Rodrigues, G.S.P.; Lengert, A.v.H.; Biondi, A.P.C.; Sargentini, L.D.B.; Brisotti, J.L.; Gomes, E.; de Oliveira, G.L.V.J.F.i.I. Detection of alterations in the gut microbiota and intestinal permeability in patients with Hashimoto thyroiditis. Front. Immunol. 2021, 12, 579140. [Google Scholar] [CrossRef]
  64. Sánchez-Alcoholado, L.; Ordóñez, R.; Otero, A.; Plaza-Andrade, I.; Laborda-Illanes, A.; Medina, J.A.; Ramos-Molina, B.; Gómez-Millán, J.; Queipo-Ortuño, M.I. Gut Microbiota-Mediated Inflammation and Gut Permeability in Patients with Obesity and Colorectal Cancer. Int. J. Mol. Sci. 2020, 21, 6782. [Google Scholar] [CrossRef] [PubMed]
  65. Mörkl, S.; Lackner, S.; Meinitzer, A.; Mangge, H.; Lehofer, M.; Halwachs, B.; Gorkiewicz, G.; Kashofer, K.; Painold, A.; Holl, A.K.; et al. Gut microbiota, dietary intakes and intestinal permeability reflected by serum zonulin in women. Eur. J. Nutr. 2018, 57, 2985–2997. [Google Scholar] [CrossRef] [PubMed]
  66. Vorobjova, T.; Raikkerus, H.; Kadaja, L.; Talja, I.; Uibo, O.; Heilman, K.; Uibo, R. Circulating Zonulin Correlates with Density of Enteroviruses and Tolerogenic Dendritic Cells in the Small Bowel Mucosa of Celiac Disease Patients. Dig. Dis. Sci. 2017, 62, 358–371. [Google Scholar] [CrossRef]
  67. Cangemi, R.; Pignatelli, P.; Carnevale, R.; Bartimoccia, S.; Nocella, C.; Falcone, M.; Taliani, G.; Violi, F.; Battaglia, S.; Bertazzoni, G.; et al. Low-grade endotoxemia, gut permeability and platelet activation in community-acquired pneumonia. J. Infect. 2016, 73, 107–114. [Google Scholar] [CrossRef]
  68. Carrera-Bastos, P.; Picazo, Ó.; Fontes-Villalba, M.; Pareja-Galeano, H.; Lindeberg, S.; Martínez-Selles, M.; Lucia, A.; Emanuele, E. Serum Zonulin and Endotoxin Levels in Exceptional Longevity versus Precocious Myocardial Infarction. Aging Dis. 2018, 9, 317–321. [Google Scholar] [CrossRef]
  69. Jayashree, B.; Bibin, Y.S.; Prabhu, D.; Shanthirani, C.S.; Gokulakrishnan, K.; Lakshmi, B.S.; Mohan, V.; Balasubramanyam, M. Increased circulatory levels of lipopolysaccharide (LPS) and zonulin signify novel biomarkers of proinflammation in patients with type 2 diabetes. Mol. Cell Biochem. 2014, 388, 203–210. [Google Scholar] [CrossRef]
  70. Zheng, D.; Liao, H.; Chen, S.; Liu, X.; Mao, C.; Zhang, C.; Meng, M.; Wang, Z.; Wang, Y.; Jiang, Q.; et al. Elevated Levels of Circulating Biomarkers Related to Leaky Gut Syndrome and Bacterial Translocation Are Associated With Graves’ Disease. Front. Endocrinol. 2021, 12, 796212. [Google Scholar] [CrossRef]
  71. Niewiem, M.; Grzybowska-Chlebowczyk, U.J.N. Assessment of Selected Intestinal Permeability Markers in Children with Food Allergy Depending on the Type and Severity of Clinical Symptoms. Nutrients 2022, 14, 4385. [Google Scholar] [CrossRef]
  72. Arslan, S.; Altunisik, N.; Turkmen, D.; Uremis, M.M.; Sener, S.; Turkoz, Y. Evaluation of plasma zonulin level and its relationship with inflammatory cytokines in patients with vitiligo. J. Cosmet. Dermatol. 2022, 22, 1011–1016. [Google Scholar] [CrossRef] [PubMed]
  73. Wu, H.; Wang, J.; Teng, T.; Yin, B.; He, Y.; Jiang, Y.; Liu, X.; Yu, Y.; Li, X.; Zhou, X. Biomarkers of intestinal permeability and blood-brain barrier permeability in adolescents with major depressive disorder. J. Affect. Disord. 2023, 323, 659–666. [Google Scholar] [CrossRef] [PubMed]
  74. Klaus, D.A.; Motal, M.C.; Burger-Klepp, U.; Marschalek, C.; Schmidt, E.M.; Lebherz-Eichinger, D.; Krenn, C.G.; Roth, G.A. Increased plasma zonulin in patients with sepsis. Biochem. Medica 2013, 23, 107–111. [Google Scholar] [CrossRef]
  75. Kaczmarczyk, M.; Löber, U.; Adamek, K.; Węgrzyn, D.; Skonieczna-Żydecka, K.; Malinowski, D.; Łoniewski, I.; Markó, L.; Ulas, T.; Forslund, S.K.; et al. The gut microbiota is associated with the small intestinal paracellular permeability and the development of the immune system in healthy children during the first two years of life. J. Transl. Med. 2021, 19, 1–26. [Google Scholar] [CrossRef] [PubMed]
  76. Liu, Z.-H.; Huang, M.-J.; Zhang, X.-W.; Wang, L.; Huang, N.-Q.; Peng, H.; Lan, P.; Peng, J.S.; Yang, Z.; Xia, Y.; et al. The effects of perioperative probiotic treatment on serum zonulin concentration and subsequent postoperative infectious complications after colorectal cancer surgery: A double-center and double-blind randomized clinical trial. Am. J. Clin. Nutr. 2013, 97, 117–126. [Google Scholar] [CrossRef] [PubMed]
  77. Liu, Z.; Li, C.; Huang, M.; Tong, C.; Zhang, X.; Wang, L.; Peng, H.; Lan, P.; Zhang, P.; Huang, N.; et al. Positive regulatory effects of perioperative probiotic treatment on postoperative liver complications after colorectal liver metastases surgery: A double-center and double-blind randomized clinical trial. BMC Gastroenterol. 2015, 15, 34. [Google Scholar] [CrossRef] [PubMed]
  78. Stenman, L.K.; Lehtinen, M.J.; Meland, N.; Christensen, J.E.; Yeung, N.; Saarinen, M.T.; Courtney, M.; Burcelin, R.; Lähdeaho, M.-L.; Linros, J.J.E. Probiotic with or without fiber controls body fat mass, associated with serum zonulin, in overweight and obese adults—Randomized controlled trial. EBioMedicine 2016, 13, 190–200. [Google Scholar] [CrossRef]
  79. Kantah, M.; Catanzaro, R.; Kumar, M.; Jeong, W.; Marcellino, M.J.J.G.D.S. Beneficial Gut Effect of a Symbiotic-Probiotic Regimen in Healthy Stressed Individuals: Effectiveness on Permeability, Microbiota and Detoxification Parameters. J. Gastrointest. Dig. Syst. 2018, 8, 560. [Google Scholar]
  80. Janczy, A.; Aleksandrowicz-Wrona, E.; Kochan, Z.; Małgorzewicz, S.J.A.B.P. Impact of diet and synbiotics on selected gut bacteria and intestinal permeability in individuals with excess body weight–a prospective, randomized study. Acta Biochim. Pol. 2020, 67, 571–578. [Google Scholar] [CrossRef]
  81. Lamprecht, M.; Bogner, S.; Schippinger, G.; Steinbauer, K.; Fankhauser, F.; Hallstroem, S.; Schuetz, B.; Greilberger, J.F. Probiotic supplementation affects markers of intestinal barrier, oxidation, and inflammation in trained men; a randomized, double-blinded, placebo-controlled trial. J. Int. Soc. Sports Nutr. 2012, 9, 45. [Google Scholar] [CrossRef]
  82. Wilms, E.; Gerritsen, J.; Smidt, H.; Besseling-van der Vaart, I.; Rijkers, G.T.; Garcia Fuentes, A.; Masclee, A.A.; Troost, F.J.J.P.O. Effects of supplementation of the synbiotic Ecologic® 825/FOS P6 on intestinal barrier function in healthy humans: A randomized controlled trial. PLoS ONE 2016, 11, e0167775. [Google Scholar] [CrossRef] [PubMed]
  83. Cakir, M.; Isbilen, A.A.; Eyupoglu, I.; Sag, E.; Orem, A.; Sen, T.M.; Kaklikkaya, N.; Kaya, G. Effects of long-term synbiotic supplementation in addition to lifestyle changes in children with obesity-related non-alcoholic fatty liver disease. Turk. J. Gastroenterol. 2017, 28, 377–383. [Google Scholar] [CrossRef] [PubMed]
  84. de Roos, N.M.; van Hemert, S.; Rovers, J.M.P.; Smits, M.G.; Witteman, B.J.M. The effects of a multispecies probiotic on migraine and markers of intestinal permeability–results of a randomized placebo-controlled study. Eur. J. Clin. Nutr. 2017, 71, 1455–1462. [Google Scholar] [CrossRef] [PubMed]
  85. Wegh, C.A.M.; De Roos, N.M.; Hovenier, R.; Meijerink, J.; Der Vaart, I.B.-V.; Van Hemert, S.; Witteman, B.J.M. Intestinal Permeability Measured by Urinary Sucrose Excretion Correlates with Serum Zonulin and Faecal Calprotectin Concentrations in UC Patients in Remission. J. Nutr. Metab. 2019, 2019, 2472754. [Google Scholar] [CrossRef] [PubMed]
  86. Townsend, J.R.; Bender, D.; Vantrease, W.C.; Sapp, P.A.; Toy, A.M.; Woods, C.A.; Johnson, K.D. Effects of Probiotic (Bacillus subtilis DE111) Supplementation on Immune Function, Hormonal Status, and Physical Performance in Division I Baseball Players. Sports 2018, 6, 70. [Google Scholar] [CrossRef] [PubMed]
  87. Laparra, J.; Sanz, Y. Bifidobacteria inhibit the inflammatory response induced by gliadins in intestinal epithelial cells via modifications of toxic peptide generation during digestion. J. Cell Biochem. 2010, 109, 801–807. [Google Scholar] [CrossRef] [PubMed]
  88. Gobbetti, M.; Rizzello, C.G.; Di Cagno, R.; De Angelis, M. Sourdough lactobacilli and celiac disease. Food Microbiol. 2007, 24, 187–196. [Google Scholar] [CrossRef]
  89. De Angelis, M.; Rizzello, C.G.; Fasano, A.; Clemente, M.G.; De Simone, C.; Silano, M.; De Vincenzi, M.; Losito, I.; Gobbetti, M. VSL#3 probiotic preparation has the capacity to hydrolyze gliadin polypeptides responsible for Celiac Sprue probiotics and gluten intolerance. Biochim. et Biophys. Acta (BBA) Mol. Basis Dis. 2006, 1762, 80–93. [Google Scholar] [CrossRef]
  90. Martorell, P.; Alvarez, B.; Llopis, S.; Navarro, V.; Ortiz, P.; Gonzalez, N.; Balaguer, F.; Rojas, A.; Chenoll, E.; Ramón, D. Heat-treated Bifidobacterium longum CECT-7347: A whole-cell postbiotic with antioxidant, anti-inflammatory, and gut-barrier protection properties. Antioxidants 2021, 10, 536. [Google Scholar] [CrossRef]
  91. Orlando, A.; Linsalata, M.; Notarnicola, M.; Tutino, V.; Russo, F. Lactobacillus GG restoration of the gliadin induced epithelial barrier disruption: The role of cellular polyamines. BMC Microbiol. 2014, 14, 19. [Google Scholar] [CrossRef]
  92. Xiong, W.; Huang, J.; Li, X.; Zhang, Z.; Jin, M.; Wang, J.; Xu, Y.; Wang, Z. Icariin and its phosphorylated derivatives alleviate intestinal epithelial barrier disruption caused by enterotoxigenic Escherichia coli through modulate p38 MAPK in vivo and in vitro. FASEB J. 2020, 34, 1783–1801. [Google Scholar] [CrossRef] [PubMed]
  93. Jian, C.; Kanerva, S.; Qadri, S.; Yki-Järvinen, H.; Salonen, A. In vitro Effects of Bacterial Exposure on Secretion of Zonulin Family Peptides and Their Detection in Human Tissue Samples. Front. Microbiol. 2022, 13, 848128. [Google Scholar] [CrossRef] [PubMed]
  94. Strauman, M.C.; Harper, J.M.; Harrington, S.M.; Boll, E.J.; Nataro, J.P. Enteroaggregative Escherichia coli Disrupts Epithelial Cell Tight Junctions. Infect. Immun. 2010, 78, 4958–4964. [Google Scholar] [CrossRef] [PubMed]
  95. Mukiza, C.N.; Dubreuil, J.D. Escherichia coli Heat-Stable Toxin b Impairs Intestinal Epithelial Barrier Function by Altering Tight Junction Proteins. Infect. Immun. 2013, 81, 2819–2827. [Google Scholar] [CrossRef]
  96. Brown, E.M.; Wlodarska, M.; Willing, B.P.; Vonaesch, P.; Han, J.; Reynolds, L.A.; Arrieta, M.-C.; Uhrig, M.; Scholz, R.; Partida, O.; et al. Diet and specific microbial exposure trigger features of environmental enteropathy in a novel murine model. Nat. Commun. 2015, 6, 7806. [Google Scholar] [CrossRef]
  97. Li, C.; Gao, M.; Zhang, W.; Chen, C.; Zhou, F.; Hu, Z.; Zeng, C. Zonulin Regulates Intestinal Permeability and Facilitates Enteric Bacteria Permeation in Coronary Artery Disease. Sci. Rep. 2016, 6, 29142. [Google Scholar] [CrossRef]
  98. Doguer, C.; Akalan, H.; Demirok, N.T.; Erdal, B.; Mete, R.; Bilgen, T. Protective effects of Acetobacter ghanensis against gliadin toxicity in intestinal epithelial cells with immunoregulatory and gluten-digestive properties. Eur. J. Nutr. 2022, 62, 605–614. [Google Scholar] [CrossRef]
  99. Nakajima, M.; Arimatsu, K.; Kato, T.; Matsuda, Y.; Minagawa, T.; Takahashi, N.; Ohno, H.; Yamazaki, K. Oral Administration of P. gingivalis Induces Dysbiosis of Gut Microbiota and Impaired Barrier Function Leading to Dissemination of Enterobacteria to the Liver. PLoS ONE 2015, 10, e0134234. [Google Scholar] [CrossRef]
  100. Yoseph, B.P.; Klingensmith, N.J.; Liang, Z.; Breed, E.; Burd, E.M.; Mittal, R.; Dominguez, J.A.; Petrie, B.; Ford, M.L.; Coopersmith, C.M. Mechanisms of Intestinal Barrier Dysfunction in Sepsis. Shock 2016, 46, 52–59. [Google Scholar] [CrossRef]
  101. Liu, H.; Hong, X.L.; Sun, T.T.; Huang, X.W.; Wang, J.L.; Xiong, H. Fusobacterium nucleatum exacerbates colitis by damaging epithelial barriers and inducing aberrant inflammation. J. Dig. Dis. 2020, 21, 385–398. [Google Scholar] [CrossRef]
  102. Deng, J.; Azzouz, D.F.; Ferstler, N.; Silverman, G.J.J.b. Sex-dependent Lupus Ruminococcus blautia gnavus strain induction of zonulin-mediated intestinal permeability and autoimmunity. Front. Immunol. 2022, 13, 897971. [Google Scholar]
  103. Nusrat, A.; von Eichel-Streiber, C.; Turner, J.R.; Verkade, P.; Madara, J.L.; Parkos, C.A. Clostridium difficile Toxins Disrupt Epithelial Barrier Function by Altering Membrane Microdomain Localization of Tight Junction Proteins. Infect. Immun. 2001, 69, 1329–1336. [Google Scholar] [CrossRef] [PubMed]
  104. Xu, J.; Liang, R.; Zhang, W.; Tian, K.; Li, J.; Chen, X.; Yu, T.; Chen, Q.; Tao, Y. Faecalibacterium prausnitzii-derived microbial anti-inflammatory molecule regulates intestinal integrity in diabetes mellitus mice via modulating tight junction protein expression. J. Diabetes 2020, 12, 224–236. [Google Scholar] [CrossRef] [PubMed]
  105. Xu, Q.; Li, X.; Wang, E.; He, Y.; Yin, B.; Fang, D.; Wang, G.; Zhao, J.; Zhang, H.; Chen, W. A cellular model for screening of lactobacilli that can enhance tight junctions. RSC Adv. 2016, 6, 111812–111821. [Google Scholar] [CrossRef]
  106. Ewaschuk, J.B.; Diaz, H.; Meddings, L.; Diederichs, B.; Dmytrash, A.; Backer, J.; Looijer-van Langen, M.; Madsen, K.L. Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 295, G1025–G1034. [Google Scholar] [CrossRef] [PubMed]
  107. Ahmadi, S.; Wang, S.; Nagpal, R.; Wang, B.; Jain, S.; Razazan, A.; Mishra, S.P.; Zhu, X.; Wang, Z.; Kavanagh, K.; et al. A human-origin probiotic cocktail ameliorates aging-related leaky gut and inflammation via modulating the microbiota/taurine/tight junction axis. J. Clin. Investig. 2020, 5, e132055. [Google Scholar] [CrossRef]
  108. Giorgi, A.; Cerrone, R.; Capobianco, D.; Filardo, S.; Mancini, P.; Zanni, F.; Fanelli, S.; Mastromarino, P.; Mosca, L. A Probiotic Preparation Hydrolyzes Gliadin and Protects Intestinal Cells from the Toxicity of Pro-Inflammatory Peptides. Nutrients 2020, 12, 495. [Google Scholar] [CrossRef]
  109. Bandara, M.; MacNaughton, W.K. Protease-activated receptor-2 activation enhances epithelial wound healing via epidermal growth factor receptor. Tissue Barriers 2022, 10, 1968763. [Google Scholar] [CrossRef]
  110. van der Merwe, J.Q.; Hollenberg, M.D.; MacNaughton, W.K. EGF receptor transactivation and MAP kinase mediate proteinase-activated receptor-2-induced chloride secretion in intestinal epithelial cells. Am. J. Physiol. Liver Physiol. 2008, 294, G441–G451. [Google Scholar] [CrossRef]
  111. Heijink, I.H.; van Oosterhout, A.; Kapus, A. Epidermal growth factor receptor signalling contributes to house dust mite-induced epithelial barrier dysfunction. Eur. Respir. J. 2010, 36, 1016–1026. [Google Scholar] [CrossRef]
  112. Yarden, Y.; Shilo, B.-Z. SnapShot: EGFR Signaling Pathway. Cell 2007, 131, 1018.e1–1018.e2. [Google Scholar] [CrossRef] [PubMed]
  113. Fasano, A. Intestinal Permeability and Its Regulation by Zonulin: Diagnostic and Therapeutic Implications. Clin. Gastroenterol. Hepatol. 2012, 10, 1096–1100. [Google Scholar] [CrossRef] [PubMed]
  114. Huang, L.; Fu, L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm. Sin. B 2015, 5, 390–401. [Google Scholar] [CrossRef] [PubMed]
  115. Goldblum, S.E.; Rai, U.; Tripathi, A.; Thakar, M.; De Leo, L.; Di Toro, N.; Not, T.; Ramachandran, R.; Puche, A.C.; Hollenberg, M.D. The active Zot domain (aa 288–293) increases ZO-1 and myosin 1C serine/threonine phosphorylation, alters interaction between ZO-1 and its binding partners, and induces tight junction disassembly through proteinase activated receptor 2 activation. FASEB J. 2011, 25, 144–158. [Google Scholar] [CrossRef] [PubMed]
  116. Larsson, C. Protein kinase C and the regulation of the actin cytoskeleton. Cell Signal. 2006, 18, 276–284. [Google Scholar] [CrossRef] [PubMed]
  117. Yang, Q.; Zhang, X.-F.; Van Goor, D.; Dunn, A.P.; Hyland, C.; Medeiros, N.; Forscher, P. Protein kinase C activation decreases peripheral actin network density and increases central nonmuscle myosin II contractility in neuronal growth cones. Mol. Biol. Cell 2013, 24, 3097–3114. [Google Scholar] [CrossRef] [PubMed]
  118. Veres-Székely, A.; Bernáth, M.; Pap, D.; Rokonay, R.; Szebeni, B.; Takács, I.M.; Lippai, R.; Cseh, Á.; Szabó, A.J.; Vannay, Á. PARK7 Diminishes Oxidative Stress-Induced Mucosal Damage in Celiac Disease. Oxid. Med. Cell Longev. 2020, 2020, 4787202. [Google Scholar] [CrossRef]
  119. Clemente, M.G.; De Virgiliis, S.; Kang, J.S.; Macatagney, R.; Musu, M.P.; Di Pierro, M.R.; Drago, S.; Congia, M.; Fasano, A. Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function. Gut 2003, 52, 218–223. [Google Scholar] [CrossRef]
  120. Enjoji, S.; Ohama, T.; Sato, K. Regulation of Epithelial Cell Tight Junctions by Protease-Activated Receptor 2. J. Veter Med. Sci. 2014, 76, 1225–1229. [Google Scholar] [CrossRef]
  121. Wang, J.; Kang, X.; Zhi-Qun, H.; Shen, L.; Qing, L.; Meng-Yue, L.; Li-Ping, L.; Jun-Hao, Y.; Mei, H.; Ye, J. Protease-activated receptor-2 decreased zonula occlidens-1 and claudin-1 expression and induced epithelial barrier dysfunction in allergic rhinitis. Am. J. Rhinol. Allergy 2021, 35, 26–35. [Google Scholar] [CrossRef]
  122. Vesey, D.; Suen, J.; Seow, V.; Lohman, R.-J.; Liu, L.; Gobe, G.C.; Johnson, D.W.; Fairlie, D. PAR2-induced inflammatory responses in human kidney tubular epithelial cells. Am. J. Physiol. Physiol. 2013, 304, F737–F750. [Google Scholar] [CrossRef] [PubMed]
  123. Flores-Benitez, D.; Rincon-Heredia, R.; Razgado, L.F.; Larre, I.; Cereijido, M.; Contreras, R.G. Control of tight junctional sealing: Roles of epidermal growth factor and prostaglandin E2. Am. J. Physiol. Physiol. 2009, 297, C611–C620. [Google Scholar] [CrossRef] [PubMed]
  124. Basuroy, S.; Seth, A.; Elias, B.; Naren, A.P.; Rao, R. MAPK interacts with occludin and mediates EGF-induced prevention of tight junction disruption by hydrogen peroxide. Biochem. J. 2006, 393, 69–77. [Google Scholar] [CrossRef] [PubMed]
  125. Jauregi-Miguel, A. The tight junction and the epithelial barrier in coeliac disease. Int. Rev. Cell Mol. Biol. 2020, 358, 105–132. [Google Scholar] [CrossRef]
  126. Barbaro, M.R.; Cremon, C.; Morselli-Labate, A.M.; Di Sabatino, A.; Giuffrida, P.; Corazza, G.R.; Di Stefano, M.; Caio, G.; Latella, G.; Ciacci, C.; et al. Serum zonulin and its diagnostic performance in non-coeliac gluten sensitivity. Gut 2021, 69, 1966–1974. [Google Scholar] [CrossRef]
  127. Singh, P.; Silvester, J.; Chen, X.; Xu, H.; Sawhney, V.; Rangan, V.; Iturrino, J.; Nee, J.; Duerksen, D.R.; Lembo, A. Serum zonulin is elevated in IBS and correlates with stool frequency in IBS-D. United Eur. Gastroenterol. J. 2019, 7, 709–715. [Google Scholar] [CrossRef]
  128. Rezazadegan, M.; Soheilipour, M.; Tarrahi, M.J.; Amani, R. Correlation Between Zinc Nutritional Status with Serum Zonulin and Gastrointestinal Symptoms in Diarrhea-Predominant Irritable Bowel Syndrome: A Case–Control Study. Dig. Dis. Sci. 2022, 67, 3632–3638. [Google Scholar] [CrossRef]
  129. Caviglia, G.P.; Dughera, F.; Ribaldone, D.G.; Rosso, C.; Abate, M.L.; Pellicano, R.; Bresso, F.; Smedile, A.; Saracco, G.M.; Astegiano, M. Serum zonulin in patients with inflammatory bowel disease: A pilot study. Minerva Med. 2019, 110, 95–100. [Google Scholar] [CrossRef]
  130. Tarko, A.; Suchojad, A.; Michalec, M.; Majcherczyk, M.; Brzozowska, A.; Maruniak-Chudek, I. Zonulin: A Potential Marker of Intestine Injury in Newborns. Dis. Markers 2017, 2017, 2413437. [Google Scholar] [CrossRef]
  131. Łoniewska, B.; Węgrzyn, D.; Adamek, K.; Kaczmarczyk, M.; Skonieczna-Żydecka, K.; Adler, G.; Jankowska, A.; Uzar, I.; Kordek, A.; Celewicz, M.; et al. The Influence of Maternal-Foetal Parameters on Concentrations of Zonulin and Calprotectin in the Blood and Stool of Healthy Newborns during the First Seven Days of Life. An Observational Prospective Cohort Study. J. Clin. Med. 2019, 8, 473. [Google Scholar] [CrossRef]
  132. El Wakeel, M.A.; El-Kassas, G.M.; Hashem, S.A.; Hasanin, H.M.; Ali, W.H.; Elkhatib, A.A.; Sibaii, H.; Fadl, N.N. Serum Biomarkers of Environmental Enteric Dysfunction and Growth Perspective in Egyptian Children. Open Access Maced. J. Med. Sci. 2021, 9, 1625–1632. [Google Scholar] [CrossRef]
  133. Mwape, I.; Bosomprah, S.; Mwaba, J.; Mwila-Kazimbaya, K.; Laban, N.M.; Chisenga, C.C.; Sijumbila, G.; Simuyandi, M.; Chilengi, R. Immunogenicity of rotavirus vaccine (RotarixTM) in infants with environmental enteric dysfunction. PLoS ONE 2017, 12, e0187761. [Google Scholar] [CrossRef] [PubMed]
  134. Wang, X.; Li, M.-M.; Niu, Y.; Zhang, X.; Yin, J.-B.; Zhao, C.-J.; Wang, R.-T. Serum Zonulin in HBV-Associated Chronic Hepatitis, Liver Cirrhosis, and Hepatocellular Carcinoma. Dis. Markers 2019, 2019, 5945721. [Google Scholar] [CrossRef] [PubMed]
  135. A Voulgaris, T.; Karagiannakis, D.; Hadziyannis, E.; Manolakopoulos, S.; Karamanolis, G.P.; Papatheodoridis, G.; Vlachogiannakos, J. Serum zonulin levels in patients with liver cirrhosis: Prognostic implications. World J. Hepatol. 2021, 13, 1394–1404. [Google Scholar] [CrossRef] [PubMed]
  136. De Munck, T.J.I.; Xu, P.; Verwijs, H.J.A.; Masclee, A.A.M.; Jonkers, D.; Verbeek, J.; Koek, G.H. Intestinal permeability in human nonalcoholic fatty liver disease: A systematic review and meta-analysis. Liver Int. 2020, 40, 2906–2916. [Google Scholar] [CrossRef]
  137. Sapone, A.; de Magistris, L.; Pietzak, M.; Clemente, M.G.; Tripathi, A.; Cucca, F.; Lampis, R.; Kryszak, D.; Cartenì, M.; Generoso, M.; et al. Zonulin Upregulation Is Associated With Increased Gut Permeability in Subjects With Type 1 Diabetes and Their Relatives. Diabetes 2006, 55, 1443–1449. [Google Scholar] [CrossRef]
  138. Watts, T.; Berti, I.; Sapone, A.; Gerarduzzi, T.; Not, T.; Zielke, R.; Fasano, A. Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats. Proc. Natl. Acad. Sci. USA 2005, 102, 2916–2921. [Google Scholar] [CrossRef]
  139. Mønsted, M.; Falck, N.D.; Pedersen, K.; Buschard, K.; Holm, L.J.; Haupt-Jorgensen,, M. Intestinal permeability in type 1 diabetes: An updated comprehensive overview. J. Autoimmun. 2021, 122, 102674. [Google Scholar] [CrossRef]
  140. Yuan, J.-H.; Xie, Q.-S.; Chen, G.-C.; Huang, C.-L.; Yu, T.; Chen, Q.-K.; Li, J.-Y. Impaired intestinal barrier function in type 2 diabetic patients measured by serum LPS, Zonulin, and IFABP. J. Diabetes Complicat. 2021, 35, 107766. [Google Scholar] [CrossRef]
  141. Olivieri, F.; Maguolo, A.; Corradi, M.; Zusi, C.; Huber, V.; Fornari, E.; Morandi, A.; Maffeis, C. Serum zonulin as an index of glucose dysregulation in children and adolescents with overweight and obesity. Pediatr. Obes. 2022, 17, e12946. [Google Scholar] [CrossRef]
  142. Mokkala, K.; Pellonperä, O.; Röytiö, H.; Pussinen, P.; Rönnemaa, T.; Laitinen, K. Increased intestinal permeability, measured by serum zonulin, is associated with metabolic risk markers in overweight pregnant women. Metabolism 2017, 69, 43–50. [Google Scholar] [CrossRef] [PubMed]
  143. Moreno-Navarrete, J.M.; Sabater, M.; Ortega, F.; Ricart, W.; Fernández-Real, J.M. Circulating Zonulin, a Marker of Intestinal Permeability, Is Increased in Association with Obesity-Associated Insulin Resistance. PLoS ONE 2012, 7, e37160. [Google Scholar] [CrossRef] [PubMed]
  144. Ohlsson, B.; Orho-Melander, M.; Nilsson, P.M. Higher Levels of Serum Zonulin May Rather Be Associated with Increased Risk of Obesity and Hyperlipidemia, Than with Gastrointestinal Symptoms or Disease Manifestations. Int. J. Mol. Sci. 2017, 18, 582. [Google Scholar] [CrossRef]
  145. Zhang, D.; Zhang, L.; Yue, F.; Zheng, Y.; Russell, R. Serum zonulin is elevated in women with polycystic ovary syndrome and correlates with insulin resistance and severity of anovulation. Eur. J. Endocrinol. 2015, 172, 29–36. [Google Scholar] [CrossRef]
  146. Parker, J.; O’Brien, C.; Hawrelak, J. A narrative review of the role of gastrointestinal dysbiosis in the pathogenesis of polycystic ovary syndrome. Obstet. Gynecol. Sci. 2022, 65, 14–28. [Google Scholar] [CrossRef] [PubMed]
  147. Mokkala, K.; Tertti, K.; Rönnemaa, T.; Vahlberg, T.; Laitinen, K. Evaluation of serum zonulin for use as an early predictor for gestational diabetes. Nutr. Diabetes 2017, 7, e253. [Google Scholar] [CrossRef]
  148. Güvey, H.; Çelik, S.; Çalışkan, C.S.; Yılmaz, Z.; Yılmaz, M.; Erten, Ö.; Tinelli, A. How Do Serum Zonulin Levels Change in Gestational Diabetes Mellitus, Pregnancy Cholestasis, and the Coexistence of Both Diseases? Int. J. Environ. Res. Public Health 2021, 18, 12555. [Google Scholar] [CrossRef]
  149. Demir, E.; Ozkan, H.; Seckin, K.D.; Sahtiyancı, B.; Demir, B.; Tabak, O.; Kumbasar, A.; Uzun, H. Plasma Zonulin Levels as a Non-Invasive Biomarker of Intestinal Permeability in Women with Gestational Diabetes Mellitus. Biomolecules 2019, 9, 24. [Google Scholar] [CrossRef]
  150. Oral, S.; Celik, S.; Akpak, Y.K.; Golbasi, H.; Bayraktar, B.; Unver, G.; Sahin, S.; Yurtcu, N.; Caliskan, C.S. Prediction of gestational diabetes mellitus and perinatal outcomes by plasma zonulin levels. Arch. Gynecol. Obstet. 2022, 1–8. [Google Scholar] [CrossRef]
  151. Daneshvar, M.; Yadegari, A.; Ribaldone, D.G.; Hasanzadeh, M.; Djafarian, K. Zonulin levels in complicated pregnancy: A systematic review and meta-analysis. J. Obstet. Gynaecol. 2022, 42, 2621–2628. [Google Scholar] [CrossRef]
  152. Yilmaz, Z.; Oral, S.; Yurtcu, N.; Akpak, Y.K.; Celik, S.; Caliskan, C. Predictive and Prognostic Value of Plasma Zonulin for Gestational Diabetes Mellitus in Women at 24–28 Weeks of Gestation. Z. Geburtshilfe Neonatol. 2022, 226, 358–390. [Google Scholar] [CrossRef] [PubMed]
  153. Tajik, N.; Frech, M.; Schulz, O.; Schälter, F.; Lucas, S.; Azizov, V.; Dürholz, K.; Steffen, F.; Omata, Y.; Rings, A.; et al. Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis. Nat. Commun. 2020, 11, 1995. [Google Scholar] [CrossRef] [PubMed]
  154. Chmielińska, M.; Olesińska, M.; Romanowska-Próchnicka, K.; Szukiewicz, D. Haptoglobin and Its Related Protein, Zonulin—What Is Their Role in Spondyloarthropathy? J. Clin. Med. 2021, 10, 1131. [Google Scholar] [CrossRef] [PubMed]
  155. Audo, R.; Sanchez, P.; Rivière, B.; Mielle, J.; Tan, J.; Lukas, C.; Macia, L.; Morel, J.; Daien, C.I. Rheumatoid arthritis is associated with increased gut permeability and bacterial translocation that are reversed by inflammation control. Rheumatology 2022, 62, 1264–1271. [Google Scholar] [CrossRef] [PubMed]
  156. Ahmad, F.; Karim, A.; Khan, J.; Qaisar, R. Plasma zonulin correlates with cardiac dysfunction and poor physical performance in patients with chronic heart failure. Life Sci. 2022, 311, 121150. [Google Scholar] [CrossRef]
  157. Baioumy, S.A.; Elgendy, A.; Ibrahim, S.M.; Taha, S.I.; Fouad, S.H. Association between serum zonulin level and severity of house dust mite allergic asthma. Allergy Asthma Clin. Immunol. 2021, 17, 86. [Google Scholar] [CrossRef]
  158. Karim, A.; Muhammad, T.; Ustrana, S.; Qaisar, R. Intestinal permeability marker zonulin as a predictor of sarcopenia in chronic obstructive pulmonary disease. Respir. Med. 2021, 189, 106662. [Google Scholar] [CrossRef]
  159. Carpes, L.S.; Nicoletto, B.B.; Canani, L.H.; Rheinhemer, J.; Crispim, D.; Souza, G.C. Could serum zonulin be an intestinal permeability marker in diabetes kidney disease? PLoS ONE 2021, 16, e0253501. [Google Scholar] [CrossRef]
  160. Trachtman, H.; Gipson, D.S.; Lemley, K.V.; Troost, J.P.; Faul, C.; Morrison, D.J.; Vento, S.M.; Ahn, D.-H.; Goldberg, J.D. Plasma Zonulin Levels in Childhood Nephrotic Syndrome. Front. Pediatr. 2019, 7, 197. [Google Scholar] [CrossRef]
  161. Hasslacher, C.; Kulozik, F.; Platten, I.; Kraft, M.; Siegel, E. Serum zonulin as parameter of intestinal permeability in longstanding type 2 diabetes: Correlations with metabolism parameter and renal function. J. Diabetes, Metab. Disord. Control 2018, 5, 58–62. [Google Scholar] [CrossRef]
  162. Asbjornsdottir, B.; Snorradottir, H.; Andresdottir, E.; Fasano, A.; Lauth, B.; Gudmundsson, L.S.; Gottfredsson, M.; Halldorsson, T.I.; Birgisdottir, B.E. Zonulin-Dependent Intestinal Permeability in Children Diagnosed with Mental Disorders: A Systematic Review and Meta-Analysis. Nutrients 2020, 12, 1982. [Google Scholar] [CrossRef] [PubMed]
  163. Özyurt, G.; Öztürk, Y.; Appak, Y.; Arslan, F.D.; Baran, M.; Karakoyun, I.; Tufan, A.E.; Pekcanlar, A.A. Increased zonulin is associated with hyperactivity and social dysfunctions in children with attention deficit hyperactivity disorder. Compr. Psychiatry 2018, 87, 138–142. [Google Scholar] [CrossRef] [PubMed]
  164. Esnafoglu, E.; Cırrık, S.; Ayyıldız, S.N.; Erdil, A.; Ertürk, E.Y.; Daglı, A.; Noyan, T. Increased serum zonulin levels as an intestinal permeability marker in autistic subjects. J. Pediatr. 2017, 188, 240–244. [Google Scholar] [CrossRef]
  165. Karagözlü, S.; Dalgıç, B.; Işeri, E. The Relationship of Severity of Autism with Gastrointestinal Symptoms and Serum Zonulin Levels in Autistic Children. J. Autism Dev. Disord. 2021, 52, 623–629. [Google Scholar] [CrossRef]
  166. Kılıç, F.; Işık, Ü.; Demirdaş, A.; Doğuç, D.K.; Bozkurt, M. Serum zonulin and claudin-5 levels in patients with bipolar disorder. J. Affect. Disord. 2020, 266, 37–42. [Google Scholar] [CrossRef] [PubMed]
  167. Usta, A.; Kılıç, F.; Demirdaş, A.; Işık, Ü.; Doğuç, D.K.; Bozkurt, M. Serum zonulin and claudin-5 levels in patients with schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2021, 271, 767–773. [Google Scholar] [CrossRef]
  168. Stevens, B.R.; Goel, R.; Seungbum, K.; Richards, E.M.; Holbert, R.C.; Pepine, C.J.; Raizada, M.K. Increased human intestinal barrier permeability plasma biomarkers zonulin and FABP2 correlated with plasma LPS and altered gut microbiome in anxiety or depression. Gut 2018, 67, 1555–1557. [Google Scholar] [CrossRef]
  169. Karim, A.; Iqbal, M.S.; Muhammad, T.; Ahmad, F.; Qaisar, R. Elevated plasma zonulin and CAF22 are correlated with sarcopenia and functional dependency at various stages of Alzheimer’s diseases. Neurosci. Res. 2022, 184, 47–53. [Google Scholar] [CrossRef]
  170. Dumitrescu, L.; Marta, D.; Dănău, A.; Lefter, A.; Tulbă, D.; Cozma, L.; Manole, E.; Gherghiceanu, M.; Ceafalan, L.C.; Popescu, B.O. Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson’s Disease. Front. Neurosci. 2021, 15, 689723. [Google Scholar] [CrossRef]
  171. Camara-Lemarroy, C.R.; Silva, C.; Greenfield, J.; Liu, W.-Q.; Metz, L.M.; Yong, V.W. Biomarkers of intestinal barrier function in multiple sclerosis are associated with disease activity. Mult. Scler. J. 2020, 26, 1340–1350. [Google Scholar] [CrossRef]
  172. Galea, I. The blood–brain barrier in systemic infection and inflammation. Cell Mol. Immunol. 2021, 18, 2489–2501. [Google Scholar] [CrossRef] [PubMed]
  173. Rahman, M.T.; Ghosh, C.; Hossain, M.; Linfield, D.; Rezaee, F.; Janigro, D.; Marchi, N.; van Boxel-Dezaire, A.H. IFN-γ, IL-17A, or zonulin rapidly increase the permeability of the blood-brain and small intestinal epithelial barriers: Relevance for neuro-inflammatory diseases. Biochem. Biophys. Res. Commun. 2018, 507, 274–279. [Google Scholar] [CrossRef] [PubMed]
  174. Greene, C.; Hanley, N.; Campbell, M. Claudin-5: Gatekeeper of neurological function. Fluids Barriers CNS 2019, 16, 3. [Google Scholar] [CrossRef]
  175. Kılıç, A.O.; Akın, F.; Yazar, A.; Metin Akcan, Ö.; Topcu, C.; Aydın, O. Zonulin and claudin-5 levels in multisystem inflammatory syndrome and SARS-CoV-2 infection in children. J. Paediatr. Child Health 2022, 58, 1561–1565. [Google Scholar] [CrossRef] [PubMed]
  176. Lasek-Bal, A.; Kokot, A.; de Carrillo, D.G.; Student, S.; Pawletko, K.; Krzan, A.; Puz, P.; Bal, W.; Jędrzejowska-Szypułka, H. Plasma Levels of Occludin and Claudin-5 in Acute Stroke Are Correlated with the Type and Location of Stroke but Not with the Neurological State of Patients—Preliminary Data. Brain Sci. 2020, 10, 831. [Google Scholar] [CrossRef] [PubMed]
  177. Okuyucu, M.; Kehribar, D.Y.; Çapraz, M.; Çapraz, A.; Arslan, M.; Çelik, Z.B.; Usta, B.; Birinci, A.; Ozgen, M. The Relationship between COVID-19 Disease Severity and Zonulin Levels. Cureus 2022, 14, e28255. [Google Scholar] [CrossRef] [PubMed]
  178. Yonker, L.M.; Gilboa, T.; Ogata, A.F.; Senussi, Y.; Lazarovits, R.; Boribong, B.P.; Bartsch, Y.C.; Loiselle, M.; Rivas, M.N.; Porritt, R.A.; et al. Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier. J. Clin. Investig. 2021, 131, e149633. [Google Scholar] [CrossRef]
  179. Hensley-McBain, T.R.; Manuzak, J.A. Zonulin as a biomarker and potential therapeutic target in multisystem inflammatory syndrome in children. J. Clin. Investig. 2021, 131, e151467. [Google Scholar] [CrossRef]
  180. Llorens, S.; Nava, E.; Muñoz-López, M.; Sánchez-Larsen, Á.; Segura, T. Neurological Symptoms of COVID-19: The Zonulin Hypothesis. Front. Immunol. 2021, 12, 665300. [Google Scholar] [CrossRef]
  181. Palomino-Kobayashi, L.A.; Ymaña, B.; Ruiz, J.; Mayanga-Herrera, A.; Ugarte-Gil, M.F.; Pons, M.J. Zonulin, a marker of gut permeability, is associated with mortality in a cohort of hospitalised peruvian COVID-19 patients. Front. Cell. Infect. Microbiol. 2022, 12, 1310. [Google Scholar]
  182. Bawah, A.; Yakubu, Y.; Nanga, S. The relationship between zonulin and liver function test in patients with human immune deficiency virus infection. J. Med. Lab. Sci. Technol. S. Afr. 2021, 3, 71–76. [Google Scholar]
  183. Pastor, L.; Langhorst, J.; Schröder, D.; Casellas, A.; Ruffer, A.; Carrillo, J.; Urrea, V.; Massora, S.; Mandomando, I.; Blanco, J.; et al. Different pattern of stool and plasma gastrointestinal damage biomarkers during primary and chronic HIV infection. PLoS ONE 2019, 14, e0218000. [Google Scholar] [CrossRef] [PubMed]
  184. A Koay, W.L.; Lindsey, J.C.; Uprety, P.; Bwakura-Dangarembizi, M.; Weinberg, A.; Levin, M.J.; Persaud, D. Intestinal Integrity Biomarkers in Early Antiretroviral-Treated Perinatally HIV-1–Infected Infants. J. Infect. Dis. 2018, 218, 1085–1089. [Google Scholar] [CrossRef]
  185. Akao, T.; Morita, A.; Onji, M.; Miyake, T.; Watanabe, R.; Uehara, T.; Kawasaki, K.; Miyaike, J.; Oomoto, M. Low serum levels of zonulin in patients with HCV-infected chronic liver diseases. Euroasian J. Hepato-Gastroenterol. 2018, 8, 112. [Google Scholar]
  186. Calgin, M.K.; Cetinkol, Y. Decreased levels of serum zonulin and copeptin in chronic Hepatitis-B patients. Pak. J. Med. Sci. 2019, 35, 847–851. [Google Scholar] [CrossRef] [PubMed]
  187. Kuhlmann, C.R.; Tamaki, R.; Gamerdinger, M.; Lessmann, V.; Behl, C.; Kempski, O.S.; Luhmann, H.J. Inhibition of the myosin light chain kinase prevents hypoxia-induced blood-brain barrier disruption. J. Neurochem. 2007, 102, 501–507. [Google Scholar] [CrossRef] [PubMed]
  188. Yang, Y.; Thompson, J.F.; Taheri, S.; Salayandia, V.M.; McAvoy, T.A.; Hill, J.W.; Yang, Y.; Estrada, E.Y.; A Rosenberg, G. Early Inhibition of MMP Activity in Ischemic Rat Brain Promotes Expression of Tight Junction Proteins and Angiogenesis During Recovery. J. Cereb. Blood Flow Metab. 2013, 33, 1104–1114. [Google Scholar] [CrossRef]
  189. Cui, J.; Chen, S.; Zhang, C.; Meng, F.; Wu, W.; Hu, R.; Hadass, O.; Lehmidi, T.; Blair, G.J.; Lee, M.; et al. Inhibition of MMP-9 by a selective gelatinase inhibitor protects neurovasculature from embolic focal cerebral ischemia. Mol. Neurodegener. 2012, 7, 21. [Google Scholar] [CrossRef]
  190. Candelario-Jalil, E.; Taheri, S.; Yang, Y.; Sood, R.; Grossetete, M.; Estrada, E.Y.; Fiebich, B.L.; Rosenberg, G.A. Cyclooxygenase Inhibition Limits Blood-Brain Barrier Disruption following Intracerebral Injection of Tumor Necrosis Factor-α in the Rat. Experiment 2007, 323, 488–498. [Google Scholar] [CrossRef]
  191. Wu, G.; Jiao, Y.; Wu, J.; Ren, S.; Wang, L.; Tang, Z.; Zhou, H. Rosiglitazone Infusion Therapy Following Minimally Invasive Surgery for Intracranial Hemorrhage Evacuation Decreased Perihematomal Glutamate Content and Blood-Brain Barrier Permeability in Rabbits. World Neurosurg. 2018, 111, e40–e46. [Google Scholar] [CrossRef]
  192. Wu, G.; Wu, J.; Jiao, Y.; Wang, L.; Wang, F.; Zhang, Y. Rosiglitazone infusion therapy following minimally invasive surgery for intracerebral hemorrhage evacuation decreases matrix metalloproteinase-9 and blood-brain barrier disruption in rabbits. BMC Neurol. 2015, 15, 37. [Google Scholar] [CrossRef] [PubMed]
  193. Culman, J.; Nguyen-Ngoc, M.; Glatz, T.; Gohlke, P.; Herdegen, T.; Zhao, Y. Treatment of rats with pioglitazone in the reperfusion phase of focal cerebral ischemia: A preclinical stroke trial. Exp. Neurol. 2012, 238, 243–253. [Google Scholar] [CrossRef] [PubMed]
  194. Huang, T.; Gao, D.; Hei, Y.; Zhang, X.; Chen, X.; Fei, Z. D-allose protects the blood brain barrier through PPARγ-mediated anti-inflammatory pathway in the mice model of ischemia reperfusion injury. Brain Res. 2016, 1642, 478–486. [Google Scholar] [CrossRef] [PubMed]
  195. Slifer, Z.M.; Krishnan, B.R.; Madan, J.; Blikslager, A.T. Larazotide acetate: A pharmacological peptide approach to tight junction regulation. Am. J. Physiol. Liver Physiol. 2021, 320, G983–G989. [Google Scholar] [CrossRef] [PubMed]
  196. Safety of Larazotide Acetate in Healthy Volunteers. Available online: https://clinicaltrials.gov/ct2/show/NCT00386490 (accessed on 17 March 2023).
  197. Safety Study of Larazotide Acetate to Treat Celiac Disease. Available online: https://clinicaltrials.gov/ct2/show/NCT00386165f (accessed on 17 March 2023).
  198. A Leffler, D.; Kelly, C.P.; Abdallah, H.Z.; Colatrella, A.M.; A Harris, L.; Leon, F.; A Arterburn, L.; Paterson, B.M.; Lan, Z.H.; Murray, J. A Randomized, Double-Blind Study of Larazotide Acetate to Prevent the Activation of Celiac Disease During Gluten Challenge. Am. J. Gastroenterol. 2012, 107, 1554–1562. [Google Scholar] [CrossRef]
  199. Paterson, B.M.; Lammers, K.M.; Arrieta, M.C.; Fasano, A.; Meddings, J.B. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: A proof of concept study. Aliment. Pharmacol. Ther. 2007, 26, 757–766. [Google Scholar] [CrossRef]
  200. Fasano, A.; Paterson, B. Materials and Methods for the Treatment of Celiac Disease. U.S. Patent 8034776B2, 11 November 2011. [Google Scholar]
  201. Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects. Available online: https://clinicaltrials.gov/ct2/show/NCT00362856 (accessed on 17 March 2023).
  202. Pérez, L.C.; León, F. Clinical trial data provides hope for attenuation of mucosal injury in coeliac disease. Eur. J. Intern. Med. 2012, 23, e77. [Google Scholar] [CrossRef]
  203. Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate in Subjects with Active Celiac Disease. Available online: https://clinicaltrials.gov/ct2/show/NCT00620451 (accessed on 17 March 2023).
  204. Kelly, C.P.; Green, P.H.R.; Murray, J.A.; Dimarino, A.; Colatrella, A.; Leffler, D.A.; Alexander, T.; Arsenescu, R.; Leon, F.; Jiang, J.G.; et al. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: A randomised placebo-controlled study. Aliment. Pharmacol. Ther. 2013, 37, 252–262. [Google Scholar] [CrossRef]
  205. Study to Assess the Efficacy of Larazotide Acetate for the Treatment of Celiac Disease. Available online: https://www.clinicaltrials.gov/ct2/show/NCT00492960 (accessed on 17 March 2023).
  206. Leffler, D.A.; Kelly, C.P.; Green, P.H.; Fedorak, R.; DiMarino, A.; Perrow, W.; Rasmussen, H.; Wang, C.; Bercik, P.; Bachir, N.M.; et al. Larazotide Acetate for Persistent Symptoms of Celiac Disease Despite a Gluten-Free Diet: A Randomized Controlled Trial. Gastroenterology 2015, 148, 1311–1319.e6. [Google Scholar] [CrossRef]
  207. A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease. Available online: https://www.clinicaltrials.gov/ct2/show/NCT01396213 (accessed on 17 March 2023).
  208. Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms. Available online: https://clinicaltrials.gov/ct2/show/NCT03569007 (accessed on 17 March 2023).
  209. Machado, M.V. New Developments in Celiac Disease Treatment. Int. J. Mol. Sci. 2023, 24, 945. [Google Scholar] [CrossRef]
  210. Yonker, L.M.; Swank, Z.; Gilboa, T.; Senussi, Y.M.; Kenyon, V.B.; Papadakis, L.B.; Boribong, B.P.; Carroll, R.W.M.; Walt, D.R.; Fasano, A. Zonulin Antagonist, Larazotide (AT1001), As an Adjuvant Treatment for Multisystem Inflammatory Syndrome in Children: A Case Series. Crit. Care Explor. 2022, 10, e0641. [Google Scholar] [CrossRef] [PubMed]
  211. AT1001 for the Treatment of COVID-19 Related MIS-C. Available online: https://clinicaltrials.gov/ct2/show/NCT05022303 (accessed on 17 March 2023).
  212. Al Refaei, A. Larazotide acetate as a preventive and therapeutic pharmacotherapy in obesity and metabolic syndrome. Med. Hypotheses 2022, 167, 110940. [Google Scholar] [CrossRef]
  213. Gopalakrishnan, S.; Durai, M.; Kitchens, K.; Tamiz, A.P.; Somerville, R.; Ginski, M.; Paterson, B.M.; Murray, J.A.; Verdu, E.F.; Alkan, S.S.; et al. Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides 2012, 35, 86–94. [Google Scholar] [CrossRef] [PubMed]
  214. Silva, M.A.; Jury, J.; Sanz, Y.; Wiepjes, M.; Huang, X.; Murray, J.; David, C.S.; Fasano, A.; Verdú, E.F. Increased Bacterial Translocation in Gluten-Sensitive Mice Is Independent of Small Intestinal Paracellular Permeability Defect. Dig. Dis. Sci. 2012, 57, 38–47. [Google Scholar] [CrossRef] [PubMed]
  215. Liu, Z.; Shen, T.; Chen, H.; Zhou, Y.; Zhang, P.; Ma, Y.; Moyer, M.P.; Zhang, M.; Chu, Z.; Qin, H. Functional characterization of MIMP for its adhesion to the intestinal epithelium. Front. Biosci. 2011, 16, 2106–2127. [Google Scholar] [CrossRef] [PubMed]
  216. Arrieta, M.C.; Madsen, K.; Doyle, J.; Meddings, J. Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse. Gut 2008, 58, 41–48. [Google Scholar] [CrossRef]
  217. Sturgeon, C.; Lan, J.; Fasano, A. Zonulin transgenic mice show altered gut permeability and increased morbidity/mortality in the DSS colitis model. Ann. N. Y. Acad. Sci. 2017, 1397, 130–142. [Google Scholar] [CrossRef]
  218. Kwak, S.Y.; Jang, W.I.; Park, S.; Cho, S.S.; Lee, S.B.; Kim, M.-J.; Park, S.; Shim, S.; Jang, H. Metallothionein 2 activation by pravastatin reinforces epithelial integrity and ameliorates radiation-induced enteropathy. Ebiomedicine 2021, 73, 103641. [Google Scholar] [CrossRef]
  219. Enomoto, H.; Yeatts, J.; Carbajal, L.; Krishnan, B.R.; Madan, J.P.; Laumas, S.; Blikslager, A.T.; Messenger, K.M. In vivo assessment of a delayed release formulation of larazotide acetate indicated for celiac disease using a porcine model. PLoS ONE 2021, 16, e0249179. [Google Scholar] [CrossRef]
  220. Matei, D.E.; Menon, M.; Alber, D.G.; Smith, A.M.; Nedjat-Shokouhi, B.; Fasano, A.; Magill, L.; Duhlin, A.; Bitoun, S.; Gleizes, A.; et al. Intestinal barrier dysfunction plays an integral role in arthritis pathology and can be targeted to ameliorate disease. Med 2021, 2, 864–883.e9. [Google Scholar] [CrossRef]
  221. Rivas, M.N.; Wakita, D.; Franklin, M.K.; Carvalho, T.T.; Abolhesn, A.; Gomez, A.C.; Fishbein, M.C.; Chen, S.; Lehman, T.J.; Sato, K.; et al. Intestinal Permeability and IgA Provoke Immune Vasculitis Linked to Cardiovascular Inflammation. Immunity 2019, 51, 508–521.e6. [Google Scholar] [CrossRef] [PubMed]
  222. Shirey, K.; Lai, W.; Patel, M.; Pletneva, L.; Pang, C.; Kurt-Jones, E.; Lipsky, M.; Roger, T.; Calandra, T.; Tracey, K.; et al. Novel strategies for targeting innate immune responses to influenza. Mucosal Immunol. 2016, 9, 1173–1182. [Google Scholar] [CrossRef] [PubMed]
  223. Mao, X.; Min, S.; Zhu, M.; He, L.; Zhang, Y.; Li, J.; Tian, Y.; Yu, G.; Wu, L.; Cong, X. The Role of Endothelial Barrier Function in the Fibrosis of Salivary Gland. J. Dent. Res. 2022, 102, 82–92. [Google Scholar] [CrossRef] [PubMed]
  224. Caffrey, R.; Marioneaux, J.; Bhat, M.; Prior, C.; Madan, J.; Laumas, S.; Sanyal, A. FRI-267-Serial measurement of serum dextran absorption by novel competition ELISA demonstrates larazotide acetate significantly improves “leaky gut” in a Western diet murine model of metabolic liver disease. J. Hepatol. 2019, 70, e511–e512. [Google Scholar] [CrossRef]
  225. Caliskan, A.R.; Gul, M.; Yılmaz, I.; Otlu, B.; Uremis, N.; Uremis, M.M.; Kilicaslan, I.; Gul, S.; Tikici, D.; Saglam, O.; et al. Effects of larazotide acetate, a tight junction regulator, on the liver and intestinal damage in acute liver failure in rats. Hum. Exp. Toxicol. 2021, 40, S693–S701. [Google Scholar] [CrossRef] [PubMed]
  226. Haddadzadegan, S.; Dorkoosh, F.; Bernkop-Schnürch, A. Oral delivery of therapeutic peptides and proteins: Technology landscape of lipid-based nanocarriers. Adv. Drug Deliv. Rev. 2022, 182, 114097. [Google Scholar] [CrossRef] [PubMed]
  227. Di Micco, S.; Musella, S.; Sala, M.; Scala, M.C.; Andrei, G.; Snoeck, R.; Bifulco, G.; Campiglia, P.; Fasano, A. Peptide derivatives of the zonulin inhibitor larazotide (AT1001) as potential anti SARS-CoV-2: Molecular modelling, synthesis and bioactivity evaluation. Int. J. Mol. Sci. 2021, 22, 9427. [Google Scholar] [CrossRef] [PubMed]
  228. Di Micco, S.; Musella, S.; Scala, M.C.; Sala, M.; Campiglia, P.; Bifulco, G.; Fasano, A. In silico analysis revealed potential anti-SARS-CoV-2 main protease activity by the zonulin inhibitor larazotide acetate. Front. Chem. 2021, 8, 628609. [Google Scholar] [CrossRef]
  229. Di Micco, S.; Rahimova, R.; Sala, M.; Scala, M.C.; Vivenzio, G.; Musella, S.; Andrei, G.; Remans, K.; Mammri, L.; Snoeck, R. Rational design of the zonulin inhibitor AT1001 derivatives as potential anti SARS-CoV-2. Eur. J. Med. Chem. 2022, 244, 114857. [Google Scholar] [CrossRef]
  230. Motlekar, N.A.; Fasano, A.; Wachtel, M.S.; Youan, B.-B.C. Zonula occludens toxin synthetic peptide derivative AT1002 enhances in vitro and in vivo intestinal absorption of low molecular weight heparin. J. Drug Target. 2006, 14, 321. [Google Scholar] [CrossRef]
  231. Li, M.; Oliver, E.; Kitchens, K.M.; Vere, J.; Alkan, S.S.; Tamiz, A.P. Structure–activity relationship studies of permeability modulating peptide AT-1002. Bioorganic Med. Chem. Lett. 2008, 18, 4584–4586. [Google Scholar] [CrossRef] [PubMed]
  232. Ding, R.; Zhao, Z.; He, J.; Tao, Y.; Zhang, H.; Yuan, R.; Sun, K.; Shi, Y. Preparation, Drug Distribution, and In Vivo Evaluation of the Safety of Protein Corona Liposomes for Liraglutide Delivery. Nanomaterials 2023, 13, 540. [Google Scholar] [CrossRef] [PubMed]
  233. Brunner, J.; Ragupathy, S.; Borchard, G. Target specific tight junction modulators. Adv. Drug Deliv. Rev. 2021, 171, 266–288. [Google Scholar] [CrossRef] [PubMed]
  234. Kim, Y.; Lee, Y.; Heo, G.; Jeong, S.; Park, S.; Yoo, J.-W.; Jung, Y.; Im, E. Modulation of Intestinal Epithelial Permeability via Protease-Activated Receptor-2-Induced Autophagy. Cells 2022, 11, 878. [Google Scholar] [CrossRef] [PubMed]
  235. Wang, Y.-J.; Yu, S.-J.; Tsai, J.-J.; Yu, C.-H.; Liao, E.-C. Antagonism of Protease Activated Receptor-2 by GB88 Reduces Inflammation Triggered by Protease Allergen Tyr-p3. Front. Immunol. 2021, 12, 557433. [Google Scholar] [CrossRef] [PubMed]
  236. Ushakumari, C.J.; Zhou, Q.L.; Wang, Y.-H.; Na, S.; Rigor, M.C.; Zhou, C.Y.; Kroll, M.K.; Lin, B.D.; Jiang, Z.Y. Neutrophil Elastase Increases Vascular Permeability and Leukocyte Transmigration in Cultured Endothelial Cells and Obese Mice. Cells 2022, 11, 2288. [Google Scholar] [CrossRef]
  237. Xu, B.; Chen, J.; Fu, J.; Yang, R.; Yang, B.; Huo, D.; Tan, C.; Chen, H.; Wang, X. Meningitic Escherichia coli-Induced Interleukin-17A Facilitates Blood–Brain Barrier Disruption via Inhibiting Proteinase 3/Protease-Activated Receptor 2 Axis. Front. Cell Neurosci. 2022, 16, 814867. [Google Scholar] [CrossRef]
  238. Liu, W.; Wang, P.; Shang, C.; Chen, L.; Cai, H.; Ma, J.; Yao, Y.; Shang, X.; Xue, Y. Endophilin-1 regulates blood–brain barrier permeability by controlling ZO-1 and occludin expression via the EGFR–ERK1/2 pathway. Brain Res. 2014, 1573, 17–26. [Google Scholar] [CrossRef]
  239. Petecchia, L.; Sabatini, F.; Usai, C.; Caci, E.; Varesio, L.; Rossi, G.A. Cytokines induce tight junction disassembly in airway cells via an EGFR-dependent MAPK/ERK1/2-pathway. Lab. Investig. 2012, 92, 1140–1148. [Google Scholar] [CrossRef]
  240. Kakei, Y.; Teraoka, S.; Akashi, M.; Hasegawa, T.; Komori, T. Changes in cell junctions induced by inhibition of epidermal growth factor receptor in oral squamous cell carcinoma cells. Exp. Ther. Med. 2017, 14, 953–960. [Google Scholar] [CrossRef]
  241. Fan, L.; Hu, L.; Yang, B.; Fang, X.; Gao, Z.; Li, W.; Sun, Y.; Shen, Y.; Wu, X.; Shu, Y.; et al. Erlotinib promotes endoplasmic reticulum stress-mediated injury in the intestinal epithelium. Toxicol. Appl. Pharmacol. 2014, 278, 45–52. [Google Scholar] [CrossRef] [PubMed]
  242. Hong, S.; Gu, Y.; Gao, Z.; Guo, L.; Guo, W.; Wu, X.; Shen, Y.; Sun, Y.; Wu, X.; Xu, Q. EGFR inhibitor-driven endoplasmic reticulum stress-mediated injury on intestinal epithelial cells. Life Sci. 2014, 119, 28–33. [Google Scholar] [CrossRef] [PubMed]
  243. Van Sebille, Y.Z.; Gibson, R.J.; Wardill, H.R.; Ball, I.A.; Keefe, D.M.; Bowen, J.M. Dacomitinib-induced diarrhea: Targeting chloride secretion with crofelemer. Int. J. Cancer 2018, 142, 369–380. [Google Scholar] [CrossRef] [PubMed]
  244. Van Sebille, Y.Z.; Gibson, R.J.; Wardill, H.R.; Secombe, K.R.; Ball, I.A.; Keefe, D.M.; Finnie, J.W.; Bowen, J.M. Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats. Int. J. Cancer 2017, 140, 2820–2829. [Google Scholar] [CrossRef]
  245. Leech, A.O.; Vellanki, S.H.; Rutherford, E.J.; Keogh, A.; Jahns, H.; Hudson, L.; O’donovan, N.; Sabri, S.; Abdulkarim, B.; Sheehan, K.M.; et al. Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings. Breast Cancer Res. 2018, 20, 140. [Google Scholar] [CrossRef]
  246. Zhou, Y.; Zhang, Y.; Zou, H.; Cai, N.; Chen, X.; Xu, L.; Kong, X.; Liu, P. The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells. Sci. Rep. 2015, 5, 8629. [Google Scholar] [CrossRef]
  247. Hirsh, V.; Blais, N.; Burkes, R.; Verma, S.; Croitoru, K. Management of Diarrhea Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Curr. Oncol. 2014, 21, 329–336. [Google Scholar] [CrossRef]
  248. Oda, K.; Matsuoka, Y.; Funahashi, A.; Kitano, H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol. Syst. Biol. 2005, 1, 2005-0010. [Google Scholar] [CrossRef]
  249. Pellegrini, C.; D’antongiovanni, V.; Miraglia, F.; Rota, L.; Benvenuti, L.; Di Salvo, C.; Testa, G.; Capsoni, S.; Carta, G.; Antonioli, L.; et al. Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology. NPJ Park. Dis. 2022, 8, 9. [Google Scholar] [CrossRef] [PubMed]
  250. Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients with Fabry Disease. Available online: https://clinicaltrials.gov/ct2/show/NCT01218659 (accessed on 17 March 2023).
  251. Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients with Fabry Disease. Available online: https://clinicaltrials.gov/ct2/show/NCT00925301 (accessed on 17 March 2023).
  252. Toll, L.; Zaveri, N.T.; E Polgar, W.; Jiang, F.; Khroyan, T.V.; Zhou, W.; Xie, X.S.; Stauber, G.B.; Costello, M.R.; Leslie, F.M. AT-1001: A High Affinity and Selective α3β4 Nicotinic Acetylcholine Receptor Antagonist Blocks Nicotine Self-Administration in Rats. Neuropsychopharmacology 2012, 37, 1367–1376. [Google Scholar] [CrossRef] [PubMed]
  253. Talley, N.J.; Holtmann, G.J.; Jones, M.; A Koloski, N.; Walker, M.M.; Burns, G.; E Potter, M.D.; Shah, A.; Keely, S. Zonulin in serum as a biomarker fails to identify the IBS, functional dyspepsia and non-coeliac wheat sensitivity. Gut 2020, 69, 1719–1722. [Google Scholar] [CrossRef] [PubMed]
  254. Hałasa, M.; Maciejewska, D.; Ryterska, K.; Baśkiewicz-Hałasa, M.; Safranow, K.; Stachowska, E. Assessing the Association of Elevated Zonulin Concentration in Stool with Increased Intestinal Permeability in Active Professional Athletes. Medicina 2019, 55, 710. [Google Scholar] [CrossRef] [PubMed]
  255. Kuzma, J.N.; Hagman, D.K.; Cromer, G.; Breymeyer, K.L.; Roth, C.L.; Foster-Schubert, K.E.; Holte, S.E.; Weigle, D.S.; Kratz, M. Intraindividual Variation in Markers of Intestinal Permeability and Adipose Tissue Inflammation in Healthy Normal-Weight to Obese AdultsBiomarker Reliability: Adipose Inflammation Gut Permeability. Cancer Epidemiol. Biomark. Prev. 2019, 28, 610–615. [Google Scholar] [CrossRef] [PubMed]
  256. Linsalata, M.; Riezzo, G.; D’attoma, B.; Clemente, C.; Orlando, A.; Russo, F. Noninvasive biomarkers of gut barrier function identify two subtypes of patients suffering from diarrhoea predominant-IBS: A case-control study. BMC Gastroenterol. 2018, 18, 1–14. [Google Scholar] [CrossRef] [PubMed]
  257. Meira de-Faria, F.; Bednarska, O.; Ström, M.; Söderholm, J.D.; Walter, S.A.; Keita, Å.V. Colonic paracellular permeability and circulating zonulin-related proteins. Scand. J. Gastroenterol. 2021, 56, 424–431. [Google Scholar] [CrossRef]
  258. Fasano, A. All disease begins in the (leaky) gut: Role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases. F1000Research 2020, 9, 69. [Google Scholar] [CrossRef]
  259. Scheffler, L.; Crane, A.; Heyne, H.; Tönjes, A.; Schleinitz, D.; Ihling, C.H.; Stumvoll, M.; Freire, R.; Fiorentino, M.; Fasano, A.; et al. Widely Used Commercial ELISA Does Not Detect Precursor of Haptoglobin2, but Recognizes Properdin as a Potential Second Member of the Zonulin Family. Front. Endocrinol. 2018, 9, 22. [Google Scholar] [CrossRef]
  260. Ajamian, M.; Steer, D.; Rosella, G.; Gibson, P.R. Serum zonulin as a marker of intestinal mucosal barrier function: May not be what it seems. PLoS ONE 2019, 14, e0210728. [Google Scholar] [CrossRef]
  261. Massier, L.; Chakaroun, R.; Kovacs, P.; Heiker, J.T. Blurring the picture in leaky gut research: How shortcomings of zonulin as a biomarker mislead the field of intestinal permeability. Gut 2021, 70, 1801–1802. [Google Scholar] [CrossRef]
  262. Sollid, L.M.; Koning, F. Lack of relationship of AT1001 to zonulin and prehaptoglobin-2: Clinical implications. Gut 2020, 70, 2211–2212. [Google Scholar] [CrossRef]
  263. Fasano, A. Zonulin measurement conundrum: Add confusion to confusion does not lead to clarity. Gut 2021, 70, 2007–2008. [Google Scholar] [CrossRef] [PubMed]
  264. Konno, T.; Martinez, E.E.; Ji, J.; Miranda-Ribera, A.; Fiorentino, M.R.; Fasano, A. Human coagulation factor X and CD5 antigen-like are potential new members of the zonulin family proteins. Biochem. Biophys. Res. Commun. 2023, 638, 127–133. [Google Scholar] [CrossRef] [PubMed]
  265. Wang, X.; Memon, A.A.; Palmér, K.; Hedelius, A.; Sundquist, J.; Sundquist, K. The association of zonulin-related proteins with prevalent and incident inflammatory bowel disease. BMC Gastroenterol. 2022, 22, 3. [Google Scholar] [CrossRef] [PubMed]
Ijms 24 07548 g001 550
Figure 1. Zonulin as a potential therapeutic target in the disorders of the central nervous system. Luminal components, including gliadin and bacteria, induce zonulin production of the intestinal epithelial cells via CXCR3. Zonulin is a TJ modulator protein, which activates EGFR and PAR2 receptors and thereby induces actin and ZO-1 disassembly, leading to increased paracellular permeability through TJ disruption. Immunogen fragments and proinflammatory cytokines enriched in the bloodstream induce neuroinflammation, which is further facilitated by circulatory zonulin released from the intestine. Inhibition of the zonulin pathway by using zonulin antagonists (e.g., larazotide acetate), EGFR inhibitors, or PAR2 modulators can preserve the barrier function of epithelial and endothelial layers in the intestine and, presumably, also in the brain. Abbreviations: CXCR3: C-X-C chemokine receptor type 3; EGFR: epidermal growth factor receptor; JAM: junctional adhesion molecule; LPS: bacterial lipopolysaccharide; PAR2: proteinase activated receptor 2; TJ: tight junction; ZO-1: zonula occludens 1.
Figure 1. Zonulin as a potential therapeutic target in the disorders of the central nervous system. Luminal components, including gliadin and bacteria, induce zonulin production of the intestinal epithelial cells via CXCR3. Zonulin is a TJ modulator protein, which activates EGFR and PAR2 receptors and thereby induces actin and ZO-1 disassembly, leading to increased paracellular permeability through TJ disruption. Immunogen fragments and proinflammatory cytokines enriched in the bloodstream induce neuroinflammation, which is further facilitated by circulatory zonulin released from the intestine. Inhibition of the zonulin pathway by using zonulin antagonists (e.g., larazotide acetate), EGFR inhibitors, or PAR2 modulators can preserve the barrier function of epithelial and endothelial layers in the intestine and, presumably, also in the brain. Abbreviations: CXCR3: C-X-C chemokine receptor type 3; EGFR: epidermal growth factor receptor; JAM: junctional adhesion molecule; LPS: bacterial lipopolysaccharide; PAR2: proteinase activated receptor 2; TJ: tight junction; ZO-1: zonula occludens 1.
Ijms 24 07548 g001
Table
Table 1. Correlation between zonulin levels and the abundance of certain bacterial species based on literary data of descriptive human studies.
Table 1. Correlation between zonulin levels and the abundance of certain bacterial species based on literary data of descriptive human studies.
Gut Microbiome MemberPopulationZonulin Levels in Relation with Microbial AbundanceRef.
Escherichia coliankylosing spondylitis patients ↑[59]
relatively healthy elderly volunteers↑[60]
healthy adult volunteers↑[61]
Bacteroidesnormal weight and obese volunteers↑[62]
Hashimoto-thyroiditis patients↑[63]
Prevotellaankylosing spondylitis patients ↑[59]
obese colorectal carcinoma patients↑[64]
Pseudomonasrelatively healthy elderly volunteers↑[60]
Shigella↑
γ-Proteobacteria↑
Rhizobiales↑
Firmicutesnormal weight and obese volunteers↑[62]
Erysipelotrichaleshealthy women ↑[65]
Actinobacteriarelatively healthy elderly volunteers↑[60]
Clostridiumhealthy adult volunteers ↑[61]
Enteroviridaeceliac disease with or without T1D↑[66]
LPS (in serum)community-acquired pneumonia patients↑[67]
precocious acute myocardial infarction patients↑[68]
T1D↑[69]
Graves’ disease patients↑[70]
children with IgE mediated and non-IgE-mediated food allergy↑ [71]
vitiligo patients↑[72]
adolescents with major depressive disorder↑[73]
septic patients↑[74]
Lachnoclostridiumhealthy newborns↑[75]
Ruminococcus gnavus↑
Ruminococcus torques↑
Erysipelotrichales↑
Coriobacteriales↑
Alphaproteobacteria↓
Corynebacterium↓
Pdeudomonadales↓
Moraxellaceae↓
Staphylococcus↓
BifidobacteriumHashimoto-thyroiditis patients↓[63]
Lactobacillus spp. healthy adult volunteers ↓[61]
Ruminococcaceaehealthy women↓[65]
Faecalibacterium↓
Odoribacter↓
Rikenellaceae↓
Abbreviations: LPS: lipopolysaccharide; Ref.: reference; T1D: type 1 diabetes; ↑: increased expression; ↓: decreased expression.
Table
Table 2. Effect of mixtures of various bacterial species on zonulin levels based on literary data of randomized, interventional human clinical studies. Species separated by dashed lines indicate the elements of a multi-component treatment.
Table 2. Effect of mixtures of various bacterial species on zonulin levels based on literary data of randomized, interventional human clinical studies. Species separated by dashed lines indicate the elements of a multi-component treatment.
SpeciesStrainTreatment and PopulationFindingsRef.
Blood ZonulinFecal
Zonulin
Lactobacillus plantarumCGMCC no.1258pre- and postoperative probiotic treatment of patients operated on for colorectal carcinoma↓NE[76]
Lactobacillus acidophilus11
Bifidobacterium longum88
Lactobacillus plantarumCGMCC no.1258pre- and postoperative probiotic treatment of patients operated on for colorectal carcinoma and liver metastasis↓NE[77]
Lactobacillus acidophilus11
Bifidobacterium longum88
Bifidobacterium animalislactis 420probiotic and fiber treatment of healthy overweight volunteers↓NE[78]
SCM-III synbiotic mixture:synbiotic treatment of healthy stressed individuals↓↓[79]
Lactobacillus acidophilus145
Lactobacillus helveticusATC15009
Bifidobacterium420probiotic treatment of healthy stressed individuals-↓
P3T/J probiotic mixture:
Bifidobacterium animalislactis Bi1
Bifidobacterium breveBbr8synbiotic and probiotic treatment of healthy stressed individuals↓↓
Lactobacillus acidophilusLA1
Lactobacillus paracasei101/37
Bifidobacterium lactisW51 dietary changes and probiotic treatment in obese patientsNE↓[80]
W52
Lactobacillus acidophilusW22
Lactobacillus paracaseiW20
Lactobacillus plantarumW21
Lactobacillus salivariusW24
Lactococcus lactisW19
Bifidobacterium bifidumW23impact of exercise in trained men treated with probioticsNE↓[81]
Bifidobacterium lactisW51
Enterococcus faeciumW54
Lactobacillus acidophilusW22
Lactobacillus brevisW63
Lactococcus lactisW58
Bifidobacterium bifidumW23synbiotic treatment of healthy volunteers-NE[82]
Bifidobacterium lactisW51
W52
Lactobacillus acidophilusW22
Lactobacillus caseiW56
Lactobacillus paracaseiW20
Lactobacillus plantarumW62
Lactobacillus salivariusW24
Lactococcus lactisW19
Bifidobacterium lactis synbiotic treatment of children with NAFLD- NE[83]
Lactobacillus acidophilus
Lactobacillus casei
Bifidobacterium bifidumW23probiotic treatment of migraine patients- -[84]
Bifidobacterium lactisW52
Lactobacillus acidophilusW37
Lactobacillus brevisW63
Lactobacillus caseiW56probiotic treatment of ulcerative colitis patients↓-[85]
Lactobacillus salivariusW24
Lactococcus lactisW19
W58
Bacillus subtilisDE111probiotic treatment of professional baseball players-NE[86]
Abbreviations: NAFLD: non-alcoholic fatty liver disease; NE: not examined; Ref.: reference; ↓: decreased level; -: no effect.
Table
Table 3. Effect of various bacterial species on zonulin and/or ZO-1 levels based on literary data of experimental studies on cell lines and animal models. Species separated by dashed lines indicate the elements of a multi-component treatment.
Table 3. Effect of various bacterial species on zonulin and/or ZO-1 levels based on literary data of experimental studies on cell lines and animal models. Species separated by dashed lines indicate the elements of a multi-component treatment.
SpeciesStrainCell Line/
Experimental Model		FindingsRef.
ZonulinZO-1
Escherichia coli6-1CaCo2↑↓,
disruption		[42]
rat, rabbit, and monkey small intestinal organoids↑NE
K-12 DH5αrabbit and monkey small intestinal organoids↑NE
21-1rabbit small intestinal organoids↑NE
K884-day-old piglets↑↓[92]
K88IPEC-J2-↓
RY13HT-29-NE[93]
K12 DH5α-NE
042, JM221T84NEdisruption[94]
055:B5 (LPS)CaCo2↑↓[52]
CaCo2↑NE[59]
HB101T84NEdisruption[95]
Bacteroidales and
Escherichia coli		 malnourished mice↑↓[96]
Salmonella typhimuriumSO1344rabbit small intestinal organoids↑NE[42]
Pseudomonas fluorescens CaCo2↑disruption[97]
Prevotella CaCo2↑NE[59]
Acetobacter ghanensis CaCo2 treated with PT-gliadin↓-[98]
Porphyromonas gingivalis healthy miceNE↓[99]
Pseudomonas aeruginosa pneumonia induced in miceNE↑[100]
Fusobacterium nucleatum CaCo2NE↓[101]
DSS-induced colitis in miceNE↓,
disruption
Ruminococcus blautia gnavusVPI C7-9germ-free mice-NE[102]
CC55_001C-NE
S107-48↑NE
S47-18-NE
Clostridium difficile toxin A and B T84NEdisruption[103]
Faecalibacterium prausnitzii MAM NCM460 transfectionNE↑[104]
Caco2 transfectionNE↑
HT-29 transfectionNE↑
diabetes mellitus induced in miceNE↑
Lactobacillus rhamnosusGGCaCo2 treated with gliadin↓↑[91]
HT-29↑NE[93]
P1HT-29 treated with PT-gliadin↓↑[105]
P2↓↑
F1↓↑
P3↓-
GG↓↑
Lactobacillus caseiC1HT-29 treated with PT-gliadin↓↑
Bifidobacterium longumCECT-7347HT-29 treated with TNF-αNE↑[90]
T84NE↑[106]
HT-29-NE[93]
Bifidobacterium
(not specified)		 CaCo2 treated with LPS↓↑[52]
LPS-induced NEC in rats↓↑
VSL#3 IEC-6 treated with hydrolyzed gliadin↓NE[89]
mouse small intestinal organoid treated with hydrolyzed gliadin↓NE
Lactobacillus paracaseiD3-5high-fat diet in old miceNE↑[107]
Lactobacillus rhamnosusD4-4
D7-5
Lactobacillus plantarumD6-2
D13-4
Enterococcus rafnosusD24-1
Enterococcus INBioD24-2
Enterococcus AviumD25-1
D25-2
D26-1
Lactobacillus paracasei101/37 LMG P-17504CaCo2 treated with PT-gliadinNE↑[108]
Lactobacillus plantarum14 D CECT 4528
Bifidobacterium animalislactis Bi1 LMG P-17502
Bifidobacterium breveBbr8 LMG P-17501
BL10 LMG P-17500
Abbreviations: DSS: dextran sulphate sodium; LPS: lipopolysaccharide; MAM: microbial anti-inflammatory molecule; NE: not examined; NEC: necrotizing enterocolitis; PT: pepsin/trypsin digested; Ref.: reference; VSL#3: Streptococcus thermophilus, Lactobacillus plantarum, L. acidophilus, L. casei, L. delbrueckii spp. bulgaricus, Bifidobacterium breve, B. longum, B. infantis; ↑: increased expression; ↓: decreased expression; -: no effect.
Table
Table 4. Human clinical studies investigating the therapeutic applicability of larazotide acetate.
Table 4. Human clinical studies investigating the therapeutic applicability of larazotide acetate.
ConditionResultsStudy
(Enrollment)		Clinical Trials IdentifierRef.
Healthygood tolerabilityPhase I
(24)		NCT00386490[196]
Celiac disease,
gluten-free diet		good tolerabilityPhase Ib
(21)		NCT00386165[197]
Celiac disease, gluten challengeimprovement in GI symptoms,
good tolerability		Phase IIa
(80)		NCT00362856[198,199,200,201]
Celiac disease, gluten challengeimprovement in histological scores,
good tolerability		Phase IIb
(105)		NCT00620451[202,203]
Celiac disease, gluten challengeimprovement in GI symptoms, decreased level of anti-tTG IgAPhase IIb
(171)		NCT00492960[204,205]
Celiac disease, persistent symptoms with gluten-free dietimprovement in GI and extra-GI symptoms,
good tolerability		Phase IIb
(342)		NCT01396213[206,207]
Celiac disease,
gluten-free diet		(terminated based on interim analysis)Phase III
(307)		NCT03569007[208,209]
COVID19—MIS-Cimprovement in clinical symptoms, decreased level of inflammatory markers and SARS-CoV-2 nucleocapsid (N) proteincase report
(1)		 [178]
COVID19—MIS-Cimprovement in GI symptoms, decreased level of SARS-CoV-2 Spike (S) proteincase series
(4)		 [210]
COVID19—MIS-C(not completed)Phase IIa
(20)		NCT05022303[211]
Abbreviations: Ref.: reference; GI: gastrointestinal; MIS-C: Multisystem Inflammatory Syndrome in Children.
Table
Table 5. Preclinical animal studies investigating the therapeutic applicability of larazotide acetate.
Table 5. Preclinical animal studies investigating the therapeutic applicability of larazotide acetate.
ModelSpeciesAdministrationDaily DoseResultsRef.
celiac diseasegliadin-sensitized HLA-HCD4/DQ8 transgenic mousep.o.
gavage		0.25 mgreduced intestinal permeability and macrophage infiltration[213]
p.o.
gavage		0.3 mgreduced intestinal permeability [214]
intestinal permeabilityIl10−/− mousep.o.
gavage		5 mgreduced intestinal permeability and inflammation[215]
spontaneous colitisp.o.
in drinking water		0.1 or 1 mg/mLreduced intestinal permeability and inflammation[216]
DSS induced colitiszonulin transgenic mousep.o.
in drinking water		1 mg/mLreduced intestinal permeability[217]
radiation-induced enteropathymousei.p.0.25 mgimproved clinical state and histological scores, inhibited bacterial translocation, elevated TJ protein levels[218]
healthy
(pharmacokinetics)		pigp.o.
capsule		0.05 mg/kgdetermining pharmacokinetics of larazotide acetate in the small intestine [219]
Ruminococcus blautia gnavus colonization germ-free mousep.o.
in drinking water		0.15 mg/mLreduced intestinal permeability[102]
spontaneous T1DBB diabetic-prone ratp.o.
in drinking water		0.01 mg/mLinhibited development of diabetes[138]
rheumatoid arthritismousep.o.
in drinking water		0.15 mg/mLattenuated arthritis[153]
Il10ra−/− mouse,
Cldn8−/− mouse		p.o.
gavage		2 × 0.05 mgreduced intestinal permeability, inflammation, and joint swelling[220]
vasculitismousei.p.0.5 mg reduced intestinal permeability and LPS translocation, prevented cardiovascular lesions[221]
LPS-induced acute lung injuryi.t.0.05 mgreduced severity, decreased inflammatory markers[12]
i.v.0.01 or 0.025 or 0.05 mg
influenzai.v.0.15 mgreduced severity of acute lung injury[222]
salivary gland fibrosisi.p.5 mg/kgimproved epithelial barrier function, ameliorated fibrosis[223]
NAFLDp.o.
in drinking water		0.1 or 1 mg/mLreduced intestinal permeability[224]
p.o.
gavage		2 × 0.03 or 2 × 0.3 mg
acute liver failureratp.o.
in drinking water 		0.01 mg/mLdecreased intestinal damage[225]
p.o.
gavage		2 × 0.03 mg
Abbreviations: Ref.: reference; p.o.: per os; i.p.: intraperitoneal; i.v. intravenous; DSS: dextran sulphate sodium; TJ: tight junction; T1D: type 1 diabetes; LPS: lipopolysaccharide; NAFLD: non-alcoholic fatty liver disease.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Veres-Székely, A.; Szász, C.; Pap, D.; Szebeni, B.; Bokrossy, P.; Vannay, Á. Zonulin as a Potential Therapeutic Target in Microbiota-Gut-Brain Axis Disorders: Encouraging Results and Emerging Questions. Int. J. Mol. Sci. 2023, 24, 7548. https://doi.org/10.3390/ijms24087548

AMA Style

Veres-Székely A, Szász C, Pap D, Szebeni B, Bokrossy P, Vannay Á. Zonulin as a Potential Therapeutic Target in Microbiota-Gut-Brain Axis Disorders: Encouraging Results and Emerging Questions. International Journal of Molecular Sciences. 2023; 24(8):7548. https://doi.org/10.3390/ijms24087548

Chicago/Turabian Style

Veres-Székely, Apor, Csenge Szász, Domonkos Pap, Beáta Szebeni, Péter Bokrossy, and Ádám Vannay. 2023. "Zonulin as a Potential Therapeutic Target in Microbiota-Gut-Brain Axis Disorders: Encouraging Results and Emerging Questions" International Journal of Molecular Sciences 24, no. 8: 7548. https://doi.org/10.3390/ijms24087548

APA Style

Veres-Székely, A., Szász, C., Pap, D., Szebeni, B., Bokrossy, P., & Vannay, Á. (2023). Zonulin as a Potential Therapeutic Target in Microbiota-Gut-Brain Axis Disorders: Encouraging Results and Emerging Questions. International Journal of Molecular Sciences, 24(8), 7548. https://doi.org/10.3390/ijms24087548

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop